Transcriptional	O
regulation	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL3	B-protein
)	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Role	O
of	O
AP-1-	B-protein
and	I-protein
octamer-binding	I-protein
proteins	I-protein
in	O
control	O
of	O
IL3	B-protein
gene	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
molecular	O
and	O
biochemical	O
basis	O
for	O
activation	O
of	O
interleukin	B-protein
3	I-protein
(	O
IL3	B-protein
)	O
gene	O
expression	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
following	O
CD3	O
and	O
CD2	O
receptor	O
stimulation	O
or	O
activation	O
by	O
phytohemagglutinin	B-protein
plus	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

Using	O
transfection	O
and	O
reporter	O
gene	O
assays	O
specifically	O
designed	O
for	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
conjunction	O
with	O
gel	O
retardation	O
assays	O
,	O
Western	O
blot	O
analyses	O
and	O
UV	O
cross-linking	O
studies	O
,	O
we	O
found	O
that	O
c-Jun	B-protein
,	O
c-Fos	B-protein
,	O
and	O
octamer-binding	B-protein
proteins	I-protein
play	O
a	O
major	O
role	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL3	B-DNA
gene	I-DNA
via	O
their	O
interaction	O
with	O
two	O
specific	O
regions	O
contained	O
within	O
the	O
IL3	B-DNA
5'-flanking	I-DNA
sequence	I-DNA
.	O

Additionally	O
,	O
the	O
region	O
between	O
bases	O
-107	B-DNA
and	I-DNA
-59	I-DNA
of	O
the	O
IL3	B-DNA
promoter	I-DNA
containing	O
putative	O
AP-2	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
motifs	I-DNA
appears	O
necessary	O
for	O
basal	O
level	O
expression	O
of	O
the	O
IL3	B-protein
gene	O
.	O

The	O
data	O
also	O
indicate	O
that	O
CD2	B-protein
receptor	O
activation	O
and	O
phytohemagglutinin	B-protein
plus	O
phorbol	O
12-myristate	O
13-acetate	O
stimulation	O
augment	O
T	O
cell	O
IL3	B-protein
gene	O
expression	O
through	O
the	O
same	O
cis-	O
and	O
trans-activating	O
signals	O
.	O

These	O
results	O
should	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
IL3	B-protein
gene	O
expression	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
|	NULL
,	NULL
©1993	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

268	NULL
,	NULL
No	NULL
.	NULL

9	NULL
,	NULL
Issue	NULL
of	NULL
March	NULL
25	NULL
,	NULL
pp	NULL
.	NULL

6209-6308	NULL
,	NULL
1993	NULL
Printed	NULL
in	NULL
U.S8	NULL
.	NULL

A.	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
Interleukin	NULL
3	NULL
(	NULL
IL3	NULL
)	NULL
in	NULL
Primary	NULL
Human	NULL
T	NULL
Lymphocytes	NULL
ROLE	NULL
OF	NULL
AP-1-	NULL
AND	NULL
OCTAMER-BINDING	NULL
PROTEINS	NULL
IN	NULL
CONTROL	NULL
OF	NULL
IL3	NULL
GENE	NULL
EXPRESSION®*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
August	NULL
17	NULL
,	NULL
1992	NULL
)	NULL
Joo-Hung	NULL
Park	NULL
}	NULL
,	NULL
Kenneth	NULL
Kaushansky§	NULL
,	NULL
and	NULL
Lee	NULL
Levitt	NULL
}	NULL
!	NULL

From	NULL
the	NULL
{	NULL
Division	NULL
of	NULL
Hematology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Stanford	NULL
California	NULL
94305	NULL
and	NULL
the	NULL
§Division	NULL
of	NULL
Hematology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Washington	NULL
,	NULL
Seattle	NULL
Washington	NULL
98195	NULL
We	NULL
have	NULL
investigated	NULL
the	NULL
molecular	NULL
and	NULL
biochemical	NULL
basis	NULL
for	NULL
activation	NULL
of	NULL
interleukin	NULL
3	NULL
(	NULL
IL3	NULL
)	NULL
gene	NULL
expression	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
following	NULL
CD3	NULL
and	NULL
CD2	NULL
receptor	NULL
stimulation	NULL
or	NULL
activation	NULL
by	NULL
phytohemagglutinin	NULL
plus	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
.	NULL

Using	NULL
transfection	NULL
and	NULL
reporter	NULL
gene	NULL
assays	NULL
specifically	NULL
designed	NULL
for	NULL
primary	NULL
T	NULL
lymphocytes	NULL
in	NULL
conjunction	NULL
with	NULL
gel	NULL
retardation	NULL
assays	NULL
,	NULL
Western	NULL
blot	NULL
analyses	NULL
and	NULL
UV	NULL
cross-linking	NULL
studies	NULL
,	NULL
we	NULL
found	NULL
that	NULL
c-Jun	NULL
,	NULL
c-Fos	NULL
,	NULL
and	NULL
octamer-binding	NULL
proteins	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
via	NULL
their	NULL
interaction	NULL
with	NULL
two	NULL
specific	NULL
regions	NULL
contained	NULL
within	NULL
the	NULL
IL3	NULL
5'-flanking	NULL
sequence	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
region	NULL
between	NULL
bases	NULL
-107	NULL
and	NULL
-59	NULL
of	NULL
the	NULL
IL3	NULL
promoter	NULL
containing	NULL
putative	NULL
AP-2	NULL
and	NULL
Spl	NULL
binding	NULL
motifs	NULL
appears	NULL
necessary	NULL
for	NULL
basal	NULL
level	NULL
expression	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
.	NULL

The	NULL
data	NULL
also	NULL
indicate	NULL
that	NULL
CD2	NULL
receptor	NULL
activation	NULL
and	NULL
phytohemagglutinin	NULL
plus	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
stimulation	NULL
augment	NULL
T	NULL
cell	NULL
IL3	NULL
gene	NULL
expression	NULL
through	NULL
the	NULL
same	NULL
cis-	NULL
and	NULL
trans-activating	NULL
signals	NULL
.	NULL

These	NULL
results	NULL
should	NULL
contribute	NULL
to	NULL
a	NULL
better	NULL
understanding	NULL
of	NULL
the	NULL
regulation	NULL
of	NULL
IL3	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Development	NULL
and	NULL
proliferation	NULL
of	NULL
hematopoietic	NULL
cells	NULL
is	NULL
primarily	NULL
regulated	NULL
by	NULL
the	NULL
effects	NULL
of	NULL
a	NULL
complex	NULL
series	NULL
of	NULL
growth	NULL
factors	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

One	NULL
such	NULL
hematopoietic	NULL
growth	NULL
factor	NULL
is	NULL
interleukin	NULL
3	NULL
(	NULL
IL3	NULL
'	NULL
or	NULL
multi-colony-stimuating	NULL
factor	NULL
)	NULL
.	NULL

IL3	NULL
is	NULL
of	NULL
particular	NULL
interest	NULL
because	NULL
it	NULL
is	NULL
a	NULL
multilineage	NULL
growth	NULL
factor	NULL
which	NULL
supports	NULL
the	NULL
in	NULL
vitro	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
giving	NULL
rise	NULL
to	NULL
monocytes	NULL
,	NULL
granulocytes	NULL
,	NULL
megakaryocytes	NULL
,	NULL
erythrocytes	NULL
,	NULL
eosinophils	NULL
,	NULL
and	NULL
mast	NULL
cells	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

IL3	NULL
is	NULL
also	NULL
capable	NULL
of	NULL
stimulating	NULL
progenitor	NULL
cell	NULL
renewal	NULL
(	NULL
1	NULL
)	NULL
.	NULL

It	NULL
is	NULL
produced	NULL
primarily	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Antigen	NULL
triggering	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
results	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
inositol	NULL
phosphates	NULL
and	NULL
diacylglycerol	NULL
,	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
as	NULL
well	NULL
as	NULL
one	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
RO1	NULL
HL	NULL
35774	NULL
,	NULL
CA	NULL
31615	NULL
,	NULL
and	NULL
5	NULL
T32	NULL
HL	NULL
07093	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

T	NULL
Recipient	NULL
of	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Research	NULL
Career	NULL
Development	NULL
Award	NULL
KO04	NULL
HL	NULL
02213-01	NULL
.	NULL

To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Room	NULL
S-161	NULL
,	NULL
Hematology	NULL
Division	NULL
,	NULL
Stanford	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
Stanford	NULL
CA	NULL
94305	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
415-723-5007	NULL
;	NULL
Fax	NULL
:	NULL
415-723-1269	NULL
.	NULL

'The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
IL3	NULL
,	NULL
interleukin	NULL
3	NULL
;	NULL
PHA	NULL
,	NULL
phytohe-magglutinin	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
CAT	NULL
,	NULL
chloram-phenicol	NULL
acetyltransferase	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
.	NULL

or	NULL
more	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
,	NULL
ultimately	NULL
resulting	NULL
in	NULL
cytokine	NULL
production	NULL
and	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
5-10	NULL
)	NULL
.	NULL

Although	NULL
these	NULL
events	NULL
appear	NULL
to	NULL
be	NULL
mimicked	NULL
by	NULL
antibodies	NULL
to	NULL
the	NULL
T	NULL
cell	NULL
CD3	NULL
or	NULL
CD2	NULL
receptor	NULL
and	NULL
by	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
plus	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
11	NULL
)	NULL
,	NULL
the	NULL
molecular	NULL
and	NULL
biochemical	NULL
events	NULL
mediating	NULL
cytokine	NULL
gene	NULL
expression	NULL
remain	NULL
largely	NULL
unknown	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
both	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
mechanisms	NULL
(	NULL
12-15	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
of	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
have	NULL
been	NULL
performed	NULL
in	NULL
established	NULL
leukemic	NULL
T	NULL
cell	NULL
lines	NULL
like	NULL
Jurkat	NULL
or	NULL
MLA	NULL
144	NULL
using	NULL
nonphysiologic	NULL
stimulants	NULL
such	NULL
as	NULL
PMA	NULL
or	NULL
PHA	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Substantial	NULL
differences	NULL
exist	NULL
in	NULL
the	NULL
biology	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
between	NULL
leukemic	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
4	NULL
,	NULL
16-20	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
no	NULL
direct	NULL
evidence	NULL
for	NULL
the	NULL
transcription	NULL
factors	NULL
mediating	NULL
the	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
has	NULL
been	NULL
provided	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
analyzed	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
and	NULL
trans-acting	NULL
factors	NULL
operational	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
PHA	NULL
or	NULL
with	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
CD3	NULL
and	NULL
CD2	NULL
.	NULL

Functional	NULL
transfection	NULL
assays	NULL
were	NULL
used	NULL
in	NULL
combination	NULL
with	NULL
gel	NULL
shift	NULL
and	NULL
UV	NULL
cross-linking	NULL
assays	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
in	NULL
part	NULL
that	NULL
the	NULL
interaction	NULL
of	NULL
c-Jun	NULL
,	NULL
c-Fos	NULL
,	NULL
and	NULL
octamer-binding	NULL
proteins	NULL
with	NULL
two	NULL
specific	NULL
sequences	NULL
within	NULL
the	NULL
IL3	NULL
5	NULL
'	NULL
-flanking	NULL
region	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Preparation	NULL
of	NULL
Peripheral	NULL
Blood	NULL
T	NULL
Lymphocytes-Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
healthy	NULL
volunteers	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Monocytes	NULL
were	NULL
removed	NULL
by	NULL
adherence	NULL
to	NULL
plastic	NULL
flasks	NULL
,	NULL
and	NULL
B	NULL
lymphocytes	NULL
were	NULL
depleted	NULL
by	NULL
nylon	NULL
wool	NULL
columns	NULL
.	NULL

The	NULL
resultant	NULL
mononuclear	NULL
cells	NULL
were	NULL
further	NULL
purified	NULL
by	NULL
discontinuous	NULL
Percoll	NULL
density	NULL
gradient	NULL
centrifugation	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Purity	NULL
as	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
was	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
.	NULL

T	NULL
cells	NULL
purified	NULL
by	NULL
this	NULL
method	NULL
contain	NULL
less	NULL
than	NULL
3	NULL
%	NULL
residual	NULL
monocytes	NULL
.	NULL

Northern	NULL
Blot	NULL
Analysis-Twenty	NULL
micrograms	NULL
of	NULL
total	NULL
cellular	NULL
RNA	NULL
were	NULL
size-fractionated	NULL
by	NULL
formaldehyde/agarose	NULL
gel	NULL
electrophoresis	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
Nytran	NULL
membrane	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
hybridized	NULL
with	NULL
cDNA	NULL
probes	NULL
for	NULL
human	NULL
IL2	NULL
(	NULL
22	NULL
)	NULL
,	NULL
human	NULL
IL3	NULL
(	NULL
3	NULL
)	NULL
,	NULL
and	NULL
human	NULL
«	NULL
-actin	NULL
(	NULL
ATCC	NULL
)	NULL
.	NULL

All	NULL
probes	NULL
were	NULL
labeled	NULL
by	NULL
random	NULL
priming	NULL
.	NULL

Blots	NULL
were	NULL
washed	NULL
in	NULL
0.5	NULL
x	NULL
SET	NULL
(	NULL
10	NULL
x	NULL
SET	NULL
=	NULL
1.5	NULL
M	NULL
NaCl	NULL
,	NULL
0.3	NULL
M	NULL
Tris	NULL
base	NULL
,	NULL
20	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
7.5	NULL
)	NULL
and	NULL
0.1	NULL
%	NULL
sodium	NULL
pyrophosphate	NULL
at	NULL
65	NULL
°C	NULL
for	NULL
1	NULL
h.	NULL
Reporter	NULL
Gene	NULL
Constructs-Construction	NULL
of	NULL
these	NULL
hybrid	NULL
genes	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
a	NULL
925-base	NULL
pair	NULL
Pstl	NULL
fragment	NULL
of	NULL
human	NULL
genomic	NULL
IL3	NULL
containing	NULL
the	NULL
-flanking	NULL
region	NULL
of	NULL
the	NULL
gene	NULL
was	NULL
subcloned	NULL
into	NULL
M13	NULL
and	NULL
sequenced	NULL
by	NULL
the	NULL
dideoxynucleotide	NULL
method	NULL
.	NULL

Using	NULL
an	NULL
introduced	NULL
BamHI	NULL
site	NULL
42	NULL
base	NULL
pairs	NULL
downstream	NULL
of	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
,	NULL
fragments	NULL
of	NULL
the	NULL
IL3	NULL
5'-flanking	NULL
region	NULL
of	NULL
successively	NULL
larger	NULL
size	NULL
were	NULL
linked	NULL
to	NULL
the	NULL
bacterial	NULL
chlor-	NULL
6299	NULL
6300	NULL
amphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
.	NULL

All	NULL
constructions	NULL
were	NULL
sequenced	NULL
for	NULL
confirmation	NULL
.	NULL

Transfection	NULL
Assays-Resting	NULL
primary	NULL
T	NULL
cells	NULL
are	NULL
refractory	NULL
to	NULL
conventional	NULL
transfection	NULL
methods	NULL
.	NULL

It	NULL
was	NULL
thus	NULL
necessary	NULL
to	NULL
establish	NULL
alternative	NULL
assay	NULL
conditions	NULL
to	NULL
analyze	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
involved	NULL
in	NULL
IL3	NULL
gene	NULL
activation	NULL
.	NULL

We	NULL
used	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
previously	NULL
described	NULL
(	NULL
23	NULL
)	NULL
prestimulation	NULL
method	NULL
.	NULL

Purified	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocytes	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
L-glutamine	NULL
,	NULL
and	NULL
antibiotics	NULL
,	NULL
supplemented	NULL
with	NULL
PHA	NULL
(	NULL
Wellcome	NULL
Diagnostics	NULL
,	NULL
Dartford	NULL
,	NULL
England	NULL
)	NULL
at	NULL
1	NULL
ug/ml	NULL
and	NULL
recombinant	NULL
IL2	NULL
(	NULL
Cetus	NULL
,	NULL
Emoryville	NULL
CA	NULL
)	NULL
at	NULL
100	NULL
units/	NULL
ml	NULL
.	NULL

After	NULL
2	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
the	NULL
nonadherent	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
three	NULL
times	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
supplemented	NULL
with	NULL
IL2	NULL
alone	NULL
at	NULL
100	NULL
units/ml	NULL
.	NULL

The	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
more	NULL
days	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
twice	NULL
,	NULL
and	NULL
used	NULL
for	NULL
transient	NULL
transfection	NULL
assays	NULL
.	NULL

Electroporation	NULL
of	NULL
cells	NULL
was	NULL
performed	NULL
by	NULL
first	NULL
resuspending	NULL
lymphocytes	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2	NULL
x	NULL
10	NULL
``	NULL
cells/0.8	NULL
ml	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
IL2	NULL
at	NULL
100	NULL
units/ml	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Plasmid	NULL
DNA	NULL
(	NULL
30	NULL
ug/30	NULL
ul	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
suspension	NULL
,	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
10	NULL
min	NULL
,	NULL
electroporated	NULL
(	NULL
Bio-Rad	NULL
,	NULL
960	NULL
microfar-ads	NULL
,	NULL
350	NULL
mV	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
electroporated	NULL
T	NULL
cells	NULL
were	NULL
transferred	NULL
to	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
IL2	NULL
(	NULL
100	NULL
units/ml	NULL
)	NULL
.	NULL

Electroporated	NULL
cells	NULL
were	NULL
incubated	NULL
without	NULL
activation	NULL
for	NULL
18	NULL
h	NULL
,	NULL
then	NULL
stimulated	NULL
for	NULL
an	NULL
additional	NULL
6	NULL
h	NULL
and	NULL
harvested	NULL
.	NULL

As	NULL
a	NULL
control	NULL
for	NULL
the	NULL
relative	NULL
efficiency	NULL
of	NULL
transfection	NULL
,	NULL
pRSV-	NULL
@	NULL
-gal	NULL
plasmid	NULL
DNA	NULL
(	NULL
15	NULL
ug	NULL
)	NULL
(	NULL
24	NULL
)	NULL
was	NULL
co-transfected	NULL
with	NULL
reporter	NULL
gene	NULL
DNA	NULL
(	NULL
30	NULL
ug	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
CAT	NULL
and	NULL
B-galactosidase	NULL
activity	NULL
and	NULL
calculated	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Preparation	NULL
of	NULL
Nuclear	NULL
Extracts-Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
26	NULL
)	NULL
,	NULL
except	NULL
that	NULL
buffer	NULL
A	NULL
was	NULL
supplemented	NULL
with	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
5	NULL
mg/m	NULL
!	NULL
)	NULL

,	NULL
spermidine	NULL
(	NULL
0.5	NULL
mM	NULL
)	NULL
,	NULL
and	NULL
spermine	NULL
(	NULL
0.15	NULL
mM	NULL
)	NULL
,	NULL
and	NULL
chromosomal	NULL
debris	NULL
was	NULL
depleted	NULL
by	NULL
centrifugation	NULL
at	NULL
X	NULL
100,000	NULL
g	NULL
for	NULL
1	NULL
h.	NULL
Gel	NULL
Retardation	NULL
Assay-Mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
duplex	NULL
oligonucleotides	NULL
derived	NULL
from	NULL
varying	NULL
regions	NULL
of	NULL
the	NULL
IL3	NULL
promoter	NULL
were	NULL
end-labeled	NULL
with	NULL
[	NULL
y-P	NULL
]	NULL
ATP	NULL
using	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

Nuclear	NULL
extract	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
1	NULL
ng	NULL
of	NULL
labeled	NULL
oligomer	NULL
for	NULL
20	NULL
min	NULL
at	NULL
20°C	NULL
.	NULL

In	NULL
competition	NULL
experiments	NULL
,	NULL
nuclear	NULL
extract	NULL
was	NULL
preincubated	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
competitor	NULL
oligonucleotide	NULL
for	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
labeled	NULL
oligomer	NULL
.	NULL

Reaction	NULL
products	NULL
were	NULL
fractionated	NULL
by	NULL
electrophoresis	NULL
through	NULL
4	NULL
%	NULL
polyacrylamide	NULL
.	NULL

For	NULL
supershift	NULL
assays	NULL
,	NULL
anti-Jun	NULL
,	NULL
anti-Fos	NULL
,	NULL
or	NULL
anti-Oct-1	NULL
or	NULL
-2	NULL
antibodies	NULL
were	NULL
incubated	NULL
at	NULL
varying	NULL
concentrations	NULL
with	NULL
the	NULL
probe-nuclear	NULL
extract	NULL
mixtures	NULL
for	NULL
a	NULL
further	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
gel	NULL
fractionation	NULL
.	NULL

When	NULL
immunodepletion	NULL
assays	NULL
were	NULL
performed	NULL
,	NULL
antibodies	NULL
were	NULL
first	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
for	NULL
30	NULL
min	NULL
before	NULL
adding	NULL
the	NULL
oligonucleotide	NULL
probe	NULL
.	NULL

DNase	NULL
I	NULL
Footprinting	NULL
Assay-DNase	NULL
I	NULL
footprinting	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
14	NULL
)	NULL
,	NULL
using	NULL
1	NULL
ng	NULL
of	NULL
an	NULL
IL3	NULL
5'-fragment	NULL
from	NULL
-313	NULL
to	NULL
+47	NULL
end-labeled	NULL
at	NULL
the	NULL
+47	NULL
terminus	NULL
with	NULL
[	NULL
y-P	NULL
]	NULL
ATP	NULL
,	NULL
10	NULL
ng	NULL
of	NULL
DNase	NULL
I	NULL
,	NULL
and	NULL
20-50	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
.	NULL

UV	NULL
Cross-linking	NULL
Studies-UV	NULL
cross-linking	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Nuclear	NULL
extract-probe	NULL
mixtures	NULL
were	NULL
transferred	NULL
to	NULL
a	NULL
96-well	NULL
titer	NULL
plate	NULL
and	NULL
irradiated	NULL
under	NULL
a	NULL
UV	NULL
lamp	NULL
(	NULL
model	NULL
UVG-54	NULL
,	NULL
short	NULL
wave	NULL
UV-254	NULL
nm	NULL
,	NULL
Ultra-Violet	NULL
Products	NULL
,	NULL
Inc.	NULL
)	NULL
at	NULL
a	NULL
distance	NULL
of	NULL
3	NULL
cm	NULL
from	NULL
a	NULL
UV	NULL
source	NULL
for	NULL
20-60	NULL
min	NULL
.	NULL

Protein-DNA	NULL
adducts	NULL
were	NULL
heated	NULL
at	NULL
100	NULL
°C	NULL
for	NULL
5	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
%	NULL
SDS	NULL
and	NULL
1	NULL
%	NULL
2-mercaptoethanol	NULL
,	NULL
and	NULL
then	NULL
electrophoresed	NULL
in	NULL
SDS-10	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
in	NULL
situ	NULL
DNA-protein	NULL
cross-linking	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
bromodeoxyuridine-substituted	NULL
DNA	NULL
probes	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
28	NULL
)	NULL
except	NULL
that	NULL
the	NULL
gel	NULL
was	NULL
irradiated	NULL
with	NULL
a	NULL
312-nm	NULL
UV	NULL
light	NULL
source	NULL
.	NULL

Western	NULL
Blot	NULL
Analyses	NULL
in	NULL
Combination	NULL
with	NULL
the	NULL
Gel	NULL
Retardation	NULL
Assay-DNA-protein	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
free	NULL
probe	NULL
as	NULL
described	NULL
in	NULL
the	NULL
gel	NULL
retardation	NULL
assay	NULL
.	NULL

DNA-protein	NULL
complex	NULL
bands	NULL
corresponding	NULL
to	NULL
AP-1	NULL
,	NULL
NF-IL3A-1	NULL
,	NULL
and	NULL
NF-IL3A-2	NULL
were	NULL
excised	NULL
from	NULL
the	NULL
wet	NULL
gel	NULL
.	NULL

The	NULL
gel	NULL
slices	NULL
were	NULL
boiled	NULL
for.5	NULL
min	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
%	NULL
SDS	NULL
and	NULL
1	NULL
%	NULL
2-mercaptoethanol	NULL
,	NULL
and	NULL
then	NULL
electrophoresed	NULL
in	NULL
SDS-10	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
crude	NULL
extract	NULL
alone	NULL
was	NULL
run	NULL
in	NULL
an	NULL
adjacent	NULL
lane	NULL
and	NULL
a	NULL
gel	NULL
slice	NULL
was	NULL
excised	NULL
from	NULL
that	NULL
lane	NULL
at	NULL
a	NULL
position	NULL
which	NULL
corresponded	NULL
to	NULL
that	NULL
of	NULL
the	NULL
DNA-protein	NULL
complex	NULL
.	NULL

A	NULL
further	NULL
control	NULL
included	NULL
an	NULL
excised	NULL
gel	NULL
slice	NULL
obtained	NULL
from	NULL
another	NULL
adjacent	NULL
lane	NULL
which	NULL
contained	NULL
only	NULL
free	NULL
labeled	NULL
DNA	NULL
probe	NULL
.	NULL

Proteins	NULL
fractionated	NULL
in	NULL
SDS	NULL
polyacrylamide	NULL
gels	NULL
were	NULL
transferred	NULL
to	NULL
Westran	NULL
membranes	NULL
(	NULL
Schleicher	NULL
&	NULL
Schuell	NULL
)	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
blocked	NULL
in	NULL
PBS	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
Stimulant	NULL
none/	NULL
OKT3	NULL
+	NULL
IL2	NULL
/	NULL
-	NULL
Anti-	NULL
CD2	NULL
Ab	NULL
/-	NULL
PHA	NULL
+	NULL
PMA	NULL
Hours	NULL
Past	NULL
Induction	NULL
O	NULL
0.25	NULL
2	NULL
6	NULL
16	NULL
025	NULL
2	NULL
6	NULL
16	NULL
0.25	NULL
2	NULL
6	NULL
16	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
.	NULL

12	NULL
13	NULL
was	NULL
6	NULL
‘	NULL
Actin	NULL
-	NULL
...	NULL
M	NULL
...	NULL
¢	NULL
FiG	NULL
.	NULL

1	NULL
.	NULL

Induction	NULL
of	NULL
IL3	NULL
gene	NULL
expression	NULL
in	NULL
prestimulated	NULL
primary	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
plus	NULL
IL2	NULL
,	NULL
anti-CD2	NULL
antibodies	NULL
,	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
.	NULL

Purified	NULL
resting	NULL
primary	NULL
T	NULL
cells	NULL
were	NULL
sequentially	NULL
prestimulated	NULL
with	NULL
PHA	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
plus	NULL
IL2	NULL
(	NULL
100	NULL
units/ml	NULL
)	NULL
for	NULL
48	NULL
h	NULL
,	NULL
then	NULL
washed	NULL
and	NULL
maintained	NULL
in	NULL
IL2	NULL
alone	NULL
for	NULL
an	NULL
additional	NULL
48	NULL
h.	NULL
Prestimulated	NULL
T	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
or	NULL
activated	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
25	NULL
ng/ml	NULL
)	NULL
plus	NULL
IL2	NULL
(	NULL
100	NULL
units/ml	NULL
)	NULL
(	NULL
lanes	NULL
2-5	NULL
)	NULL
,	NULL
anti-CD2	NULL
antibodies	NULL
(	NULL
lanes	NULL
6-9	NULL
)	NULL
,	NULL
or	NULL
PHA	NULL
(	NULL
3	NULL
ug/ml	NULL
)	NULL
plus	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

(	NULL
lanes	NULL
10-13	NULL
)	NULL
for	NULL
15	NULL
min	NULL
,	NULL
2	NULL
h	NULL
,	NULL
6	NULL
h	NULL
,	NULL
or	NULL
16	NULL
h.	NULL
Twenty	NULL
micrograms	NULL
of	NULL
cytoplasmic	NULL
RNA	NULL
prepared	NULL
from	NULL
these	NULL
cells	NULL
were	NULL
hybridized	NULL
to	NULL
probes	NULL
for	NULL
human	NULL
IL3	NULL
or	NULL
«	NULL
-actin	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
medium	NULL
alone	NULL
;	NULL
lanes	NULL
2	NULL
,	NULL
6	NULL
,	NULL
and	NULL
10	NULL
,	NULL
15	NULL
min	NULL
;	NULL
lanes	NULL
3	NULL
,	NULL
7	NULL
,	NULL
and	NULL
11	NULL
,	NULL
2	NULL
h	NULL
;	NULL
lanes	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
12	NULL
,	NULL
6	NULL
h	NULL
;	NULL
lanes	NULL
5	NULL
,	NULL
9	NULL
,	NULL
and	NULL
13	NULL
,	NULL
16	NULL
h.	NULL
Similar	NULL
results	NULL
were	NULL
found	NULL
in	NULL
three	NULL
additional	NULL
experiments	NULL
.	NULL

L3	NULL
containing	NULL
3	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
2	NULL
h.	NULL
The	NULL
blots	NULL
were	NULL
then	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
and	NULL
incubated	NULL
with	NULL
anti-c-Jun	NULL
or	NULL
anti-Oct	NULL
antibodies	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
16	NULL
h.	NULL
After	NULL
washing	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
,	NULL
the	NULL
blots	NULL
were	NULL
incubated	NULL
with	NULL
'*	NULL
``	NULL
I-labeled	NULL
protein	NULL
A	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
in	NULL
PBS	NULL
containing	NULL
3	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
1	NULL
h.	NULL
The	NULL
blots	NULL
were	NULL
finally	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
PBS	NULL
and	NULL
developed	NULL
following	NULL
exposure	NULL
to	NULL
Kodak	NULL
XAR	NULL
5	NULL
film	NULL
.	NULL

Mitogens	NULL
and	NULL
Antibodies-PMA	NULL
and	NULL
PHA	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
and	NULL
from	NULL
Wellcome	NULL
Diagnostics	NULL
,	NULL
respectively	NULL
.	NULL

Monoclonal	NULL
antibody	NULL
OKT3	NULL
(	NULL
anti-CD3	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Ortho	NULL
Diagnostic	NULL
Systems	NULL
(	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
Tl	NULL
;	NULL
and	NULL
Tll	NULL
;	NULL
(	NULL
anti-CD2	NULL
)	NULL
(	NULL
29	NULL
)	NULL
were	NULL
graciously	NULL
provided	NULL
by	NULL
E.	NULL
Reinherz	NULL
(	NULL
Boston	NULL
)	NULL
and	NULL
purified	NULL
by	NULL
adsorption	NULL
of	NULL
tissue-culture	NULL
supernatants	NULL
to	NULL
a	NULL
protein	NULL
G	NULL
column	NULL
(	NULL
Pharmacia	NULL
LKB	NULL
Biotechnology	NULL
Inc.	NULL
)	NULL
.	NULL

Rabbit	NULL
polyclonal	NULL
antiserum	NULL
specific	NULL
to	NULL
human	NULL
c-Jun	NULL
``	NULL
was	NULL
graciously	NULL
provided	NULL
by	NULL
Dr.	NULL
Tjian	NULL
.	NULL

Rabbit	NULL
polyclonal	NULL
anti-fos	NULL
M-2	NULL
antibody	NULL
was	NULL
graciously	NULL
provided	NULL
by	NULL
Dr.	NULL
Inder	NULL
Verma	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Rabbit	NULL
polyclonal	NULL
antisera	NULL
to	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
were	NULL
graciously	NULL
provided	NULL
by	NULL
Drs	NULL
.	NULL

Winship	NULL
Herr	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
)	NULL
and	NULL
Tom	NULL
Kristie	NULL
(	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

The	NULL
antisera	NULL
raised	NULL
against	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
proteins	NULL
each	NULL
specifically	NULL
interact	NULL
with	NULL
both	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
proteins	NULL
interchangeably	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

RESULTS	NULL
Establishment	NULL
of	NULL
Transfection	NULL
Conditions	NULL
for	NULL
Primary	NULL
T	NULL
Lymphocytes-Using	NULL
nuclear	NULL
run-on	NULL
analysis	NULL
,	NULL
we	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
both	NULL
human	NULL
T	NULL
cell	NULL
lines	NULL
as	NULL
well	NULL
as	NULL
primary	NULL
T	NULL
cells	NULL
actively	NULL
transcribe	NULL
the	NULL
IL3	NULL
gene	NULL
within	NULL
3	NULL
h	NULL
following	NULL
CD3	NULL
,	NULL
CD2	NULL
,	NULL
or	NULL
mitogen	NULL
plus	NULL
PMA	NULL
stimulation	NULL
(	NULL
Ref	NULL
.	NULL

14	NULL
,	NULL
as	NULL
well	NULL
as	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Purified	NULL
primary	NULL
T	NULL
cells	NULL
were	NULL
first	NULL
prestimulated	NULL
with	NULL
PHA	NULL
plus	NULL
IL2	NULL
for	NULL
48	NULL
h	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
48	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL2	NULL
alone	NULL
prior	NULL
to	NULL
electroporation	NULL
and	NULL
subsequent	NULL
activation	NULL
.	NULL

Northern	NULL
analysis	NULL
of	NULL
prestimulated	NULL
T	NULL
cells	NULL
failed	NULL
to	NULL
detect	NULL
either	NULL
IL2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
IL3	NULL
message	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Further	NULL
activation	NULL
of	NULL
prestimulated	NULL
T	NULL
cells	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
induced	NULL
signals	NULL
for	NULL
IL2	NULL
within	NULL
15	NULL
min	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
induced	NULL
IL3	NULL
message	NULL
within	NULL
2-6	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Although	NULL
anti-CD3	NULL
antibody	NULL
plus	NULL
IL2	NULL
clearly	NULL
induced	NULL
IL3	NULL
gene	NULL
expression	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
,	NULL
CD3	NULL
activation	NULL
did	NULL
not	NULL
induce	NULL
IL2	NULL
or	NULL
IL3	NULL
message	NULL
in	NULL
prestimulated	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
down-modulation	NULL
of	NULL
the	NULL
CD3	NULL
receptor	NULL
could	NULL
explain	NULL
this	NULL
observation	NULL
,	NULL
fluorescent	NULL
cell	NULL
sorter	NULL
analysis	NULL
using	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
OKT3	NULL
)	NULL
demonstrated	NULL
comparable	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
CD3	NULL
in	NULL
both	NULL
resting	NULL
and	NULL
prestimulated	NULL
T	NULL
cells	NULL
.	NULL

How	NULL
*	NULL
R.	NULL
Tjian	NULL
,	NULL
personal	NULL
communication	NULL
.	NULL

Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
ever	NULL
,	NULL
when	NULL
purified	NULL
monocytes	NULL
were	NULL
added	NULL
back	NULL
to	NULL
prestimulated	NULL
T	NULL
cells	NULL
prior	NULL
to	NULL
activation	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
plus	NULL
IL2	NULL
,	NULL
both	NULL
IL2	NULL
and	NULL
IL3	NULL
messages	NULL
were	NULL
induced	NULL
albeit	NULL
at	NULL
lower	NULL
levels	NULL
of	NULL
expression	NULL
than	NULL
those	NULL
observed	NULL
following	NULL
CD2	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
either	NULL
monocytes	NULL
or	NULL
monocyte-derived	NULL
cytokines	NULL
were	NULL
depleted	NULL
via	NULL
adherence	NULL
or	NULL
washing	NULL
during	NULL
T	NULL
cell	NULL
prestimulation	NULL
and	NULL
that	NULL
these	NULL
signals	NULL
are	NULL
a	NULL
necessary	NULL
adjunct	NULL
to	NULL
CD3	NULL
stimulation	NULL
of	NULL
primary	NULL
T	NULL
cells	NULL
;	NULL
these	NULL
results	NULL
are	NULL
in	NULL
accord	NULL
with	NULL
recent	NULL
observations	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Analyses	NULL
of	NULL
Cis-acting	NULL
DNA	NULL
Elements	NULL
Operational	NULL
in	NULL
the	NULL
Activation	NULL
of	NULL
the	NULL
IL3	NULL
Gene-IL3	NULL
reporter	NULL
gene	NULL
analysis	NULL
was	NULL
next	NULL
performed	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
barely	NULL
detectable	NULL
in	NULL
prestimulated	NULL
T	NULL
cells	NULL
transfected	NULL
with	NULL
constructs	NULL
-107	NULL
to	NULL
-356	NULL
and	NULL
assessed	NULL
without	NULL
further	NULL
activation	NULL
(	NULL
relative	NULL
CAT	NULL
activity	NULL
7.0-10.4	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
relatively	NULL
low	NULL
level	NULL
of	NULL
IL3	NULL
message	NULL
expressed	NULL
following	NULL
CD3	NULL
activation	NULL
in	NULL
prestimulated	NULL
T	NULL
cells	NULL
even	NULL
after	NULL
monocyte	NULL
supplementation	NULL
,	NULL
reporter	NULL
analysis	NULL
was	NULL
performed	NULL
primarily	NULL
with	NULL
CD2	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
activation	NULL
.	NULL

When	NULL
prestimulated	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
or	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
after	NULL
electropor-ation	NULL
,	NULL
CAT	NULL
activity	NULL
was	NULL
increased	NULL
5-22-fold	NULL
(	NULL
constructs	NULL
-356	NULL
,	NULL
-313	NULL
,	NULL
-272	NULL
,	NULL
and	NULL
-161	NULL
)	NULL
.	NULL

Little	NULL
inducible	NULL
promoter	NULL
activity	NULL
was	NULL
observed	NULL
with	NULL
constructs	NULL
-126	NULL
and	NULL
-107	NULL
(	NULL
only	NULL
a	NULL
1.5-fold	NULL
increase	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
presence	NULL
of	NULL
important	NULL
enhancing	NULL
regulatory	NULL
sequences	NULL
between	NULL
positions	NULL
-161	NULL
and	NULL
-126	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

A	NULL
second	NULL
potentially	NULL
important	NULL
enhancing	NULL
region	NULL
was	NULL
identified	NULL
between	NULL
positions	NULL
-272	NULL
and	NULL
-313	NULL
.	NULL

Deletion	NULL
of	NULL
this	NULL
region	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
consensus	NULL
binding	NULL
site	NULL
for	NULL
transcriptional	NULL
factor	NULL
AP-1	NULL
(	NULL
33	NULL
)	NULL
,	NULL
reduced	NULL
CAT	NULL
activity	NULL
by	NULL
50-70	NULL
%	NULL
.	NULL

Construct	NULL
-59	NULL
which	NULL
produced	NULL
zero	NULL
level	NULL
of	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
prestimulated	NULL
cells	NULL
,	NULL
was	NULL
also	NULL
not	NULL
inducible	NULL
following	NULL
CD2	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
activation	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
two	NULL
enhancing	NULL
regions	NULL
,	NULL
two	NULL
potentially	NULL
negative	NULL
regulatory	NULL
sites	NULL
were	NULL
also	NULL
identified	NULL
.	NULL

Addition	NULL
of	NULL
the	NULL
region	NULL
between	NULL
-161	NULL
and	NULL
-272	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
sequence	NULL
between	NULL
-313	NULL
and	NULL
-356	NULL
,	NULL
produced	NULL
a	NULL
consistent	NULL
decrease	NULL
in	NULL
reporter	NULL
activity	NULL
following	NULL
either	NULL
CD2	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
activation	NULL
.	NULL

The	NULL
region	NULL
between	NULL
-161	NULL
and	NULL
-126	NULL
contains	NULL
closely	NULL
spaced	NULL
or	NULL
overlapping	NULL
DNA	NULL
sequences	NULL
similar	NULL
to	NULL
known	NULL
consensus	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

5	NULL
deletion	NULL
analysis	NULL
of	NULL
the	NULL
human	NULL
IL3	NULL
promoter	NULL
in	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocytes	NULL
.	NULL

Prestimulated	NULL
primary	NULL
T	NULL
cells	NULL
were	NULL
co-transfected	NULL
with	NULL
30	NULL
ug	NULL
of	NULL
the	NULL
IL3	NULL
promoter-CAT	NULL
construct	NULL
and	NULL
15	NULL
ug	NULL
of	NULL
pRSV-A-gal	NULL
DNA	NULL
,	NULL
then	NULL
incubated	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
IL2	NULL
{	NULL
100	NULL
units/ml	NULL
)	NULL
for	NULL
18	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
activated	NULL
with	NULL
either	NULL
anti-CD2	NULL
antibodies	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
or	NULL
medium	NULL
alone	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
6	NULL
h	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
stimulants	NULL
and	NULL
analyzed	NULL
for	NULL
CAT	NULL
and	NULL
-galactosidase	NULL
activity	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
standardized	NULL
with	NULL
respect	NULL
to	NULL
B-galactosidase	NULL
activity	NULL
.	NULL

CAT	NULL
activity	NULL
is	NULL
expressed	NULL
relative	NULL
to	NULL
the	NULL
activity	NULL
obtained	NULL
with	NULL
construct	NULL
-313	NULL
(	NULL
in	NULL
CD2-stimulated	NULL
T	NULL
cells	NULL
)	NULL
which	NULL
was	NULL
assigned	NULL
an	NULL
arbitrary	NULL
value	NULL
of	NULL
100	NULL
.	NULL

The	NULL
results	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
four	NULL
separate	NULL
experiments	NULL
for	NULL
each	NULL
construct	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
induction	NULL
is	NULL
shown	NULL
in	NULL
paren-theses	NULL
.	NULL

For	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
5	NULL
flanking	NULL
region	NULL
of	NULL
the	NULL
IL-3	NULL
gene	NULL
,	NULL
see	NULL
Ref	NULL
.	NULL

14	NULL
.	NULL

Black	NULL
boxes	NULL
indicate	NULL
the	NULL
positions	NULL
of	NULL
site-directed	NULL
mutagenesis	NULL
.	NULL

Promoter	NULL
Fragment	NULL
___	NULL
--	NULL
_-_	NULL
--	NULL
g___p	NULL
c	NULL
___	NULL
»	NULL
___	NULL
a___	NULL
>	NULL
___P	NULL
___	NULL
_2	NULL
6301	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
for	NULL
cAMP-responsive	NULL
transcriptional	NULL
enhancer-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
(	NULL
34	NULL
)	NULL
(	NULL
-148	NULL
to	NULL
-141	NULL
)	NULL
and	NULL
both	NULL
AP-1	NULL
and	NULL
Oct	NULL
(	NULL
31	NULL
)	NULL
(	NULL
-156	NULL
to	NULL
-147	NULL
)	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
was	NULL
next	NULL
used	NULL
to	NULL
examine	NULL
this	NULL
region	NULL
in	NULL
more	NULL
detail	NULL
.	NULL

Construct	NULL
-356yrmsa	NULL
was	NULL
generated	NULL
by	NULL
mutating	NULL
the	NULL
residues	NULL
between	NULL
-156	NULL
and	NULL
-147	NULL
(	NULL
ATGAATAATT	NULL
)	NULL
to	NULL
a	NULL
random	NULL
sequence	NULL
(	NULL
CACCCGATCG	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
markedly	NULL
decreased	NULL
reporter	NULL
gene	NULL
activity	NULL
,	NULL
whereas	NULL
mutation	NULL
of	NULL
the	NULL
CREB	NULL
site	NULL
(	NULL
construct	NULL
-16lcrge	NULL
mutated	NULL
from	NULL
TTACGTCT	NULL
to	NULL
TTACGGAT	NULL
)	NULL
did	NULL
not	NULL
affect	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
Nuclear	NULL
Proteins	NULL
Responsible	NULL
for	NULL
IL3	NULL
Gene	NULL
In-duction-Gel	NULL
retardation	NULL
assays	NULL
were	NULL
next	NULL
performed	NULL
to	NULL
determine	NULL
whether	NULL
nuclear	NULL
proteins	NULL
bind	NULL
to	NULL
functional	NULL
sequences	NULL
of	NULL
the	NULL
IL3	NULL
promoter	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
prestimulated	NULL
primary	NULL
T	NULL
cells	NULL
and	NULL
from	NULL
prestimulated	NULL
cells	NULL
following	NULL
induction	NULL
with	NULL
mitogen	NULL
,	NULL
anti-CD2	NULL
or	NULL
anti-CD3	NULL
antibodies	NULL
.	NULL

When	NULL
an	NULL
oligonucleotide	NULL
probe	NULL
spanning	NULL
bases	NULL
between	NULL
-307	NULL
and	NULL
-288	NULL
(	NULL
and	NULL
containing	NULL
a	NULL
consensus	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
-301	NULL
TGAGTCA	NULL
-295	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
noninduced	NULL
nuclear	NULL
extracts	NULL
,	NULL
two	NULL
retarded	NULL
bands	NULL
were	NULL
produced	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
observed	NULL
whether	NULL
extracts	NULL
were	NULL
derived	NULL
from	NULL
resting	NULL
or	NULL
from	NULL
prestimulated	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
,	NULL
PHA	NULL
,	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
for	NULL
3	NULL
h	NULL
increased	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
upper	NULL
band	NULL
(	NULL
band	NULL
C	NULL
)	NULL
2.5-	NULL
,	NULL
3-	NULL
,	NULL
and	NULL
4-fold	NULL
,	NULL
respectively	NULL
,	NULL
whereas	NULL
no	NULL
increase	NULL
was	NULL
observed	NULL
with	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
plus	NULL
IL2	NULL
or	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

The	NULL
DNA-protein	NULL
complex	NULL
(	NULL
band	NULL
C	NULL
)	NULL
resulted	NULL
from	NULL
sequence-specific	NULL
binding	NULL
since	NULL
complex	NULL
formation	NULL
was	NULL
blocked	NULL
by	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
but	NULL
not	NULL
by	NULL
the	NULL
same	NULL
molar	NULL
amount	NULL
of	NULL
other	NULL
oligonucleotide	NULL
competitors	NULL
(	NULL
transcriptional	NULL
factor	NULL
AP2/Sp1	NULL
binding	NULL
elements	NULL
(	NULL
34	NULL
)	NULL
and	NULL
a	NULL
CK1/CK2	NULL
elememt	NULL
conserved	NULL
among	NULL
cytokine	NULL
promoters	NULL
(	NULL
2	NULL
)	NULL
)	NULL
nor	NULL
by	NULL
salmon	NULL
sperm	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
NF-IL3A	NULL
site	NULL
(	NULL
-161	NULL
to	NULL
-142	NULL
)	NULL
also	NULL
displaced	NULL
the	NULL
nuclear	NULL
protein	NULL
from	NULL
the	NULL
AP-1	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

(	NULL
The	NULL
lower	NULL
band	NULL
in	NULL
this	NULL
retardation	NULL
assay	NULL
was	NULL
constitutively	NULL
present	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
and	NULL
was	NULL
inhibited	NULL
by	NULL
nonspecific	NULL
competitors	NULL
;	NULL
further	NULL
attention	NULL
was	NULL
thus	NULL
directed	NULL
primarily	NULL
to	NULL
band	NULL
C.	NULL
)	NULL
CD2-induced	NULL
AP-1	NULL
binding	NULL
activity	NULL
appeared	NULL
relatively	NULL
transient	NULL
RELATIVE	NULL
CAT	NULL
ACTIVITY	NULL
uninduced	NULL
anti-CD2	NULL
PHA/PMA	NULL
~356	NULL
10.4	NULL
49.3	NULL
(	NULL
4.7	NULL
)	NULL
62.3	NULL
(	NULL
6.0	NULL
)	NULL
-356	NULL
6.8	NULL
17.3	NULL
(	NULL
2.5	NULL
)	NULL
20.3	NULL
(	NULL
3.0	NULL
)	NULL
NFILIA	NULL
-313	NULL
6.8	NULL
100.0	NULL
(	NULL
14.7	NULL
)	NULL
156.3	NULL
(	NULL
22.9	NULL
)	NULL
-272	NULL
7.1	NULL
51.4	NULL
(	NULL
7.2	NULL
)	NULL
46.1	NULL
(	NULL
6.5	NULL
)	NULL
-~161	NULL
6.5	NULL
62.2	NULL
(	NULL
9.6	NULL
)	NULL
63.6	NULL
(	NULL
9.8	NULL
)	NULL
+161	NULL
6.4	NULL
59.3	NULL
(	NULL
9.3	NULL
)	NULL
61.0	NULL
(	NULL
9.5	NULL
)	NULL
CREB	NULL
-126	NULL
6.7	NULL
9.9	NULL
(	NULL
1.5	NULL
)	NULL
10.3	NULL
(	NULL
1.6	NULL
)	NULL
-107	NULL
7.0	NULL
10.1	NULL
(	NULL
1.4	NULL
)	NULL
11.2	NULL
(	NULL
1.6	NULL
)	NULL
-59	NULL
0.4	NULL
0.4	NULL
(	NULL
1.0	NULL
)	NULL
0.4	NULL
(	NULL
1.0	NULL
)	NULL
6302	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
(	NULL
A	NULL
)	NULL
o	NULL
(	NULL
B	NULL
)	NULL
(	NULL
C	NULL
)	NULL
s	NULL
or	NULL
<	NULL
«	NULL
C	NULL
-	NULL
-	NULL
~	NULL
~	NULL
os	NULL
<	NULL
3	NULL
B	NULL
Z	NULL
5	NULL
§	NULL
¥	NULL
<	NULL
3	NULL
§	NULL
g	NULL
%	NULL
&	NULL
k	NULL
A	NULL
¥	NULL
Z	NULL
x	NULL
o	NULL
pt	NULL
U	NULL
:	NULL
<	NULL
<	NULL
<	NULL
Competitor	NULL
_	NULL
2	NULL
7.	NULL
i	NULL
2	NULL
>	NULL
A	NULL
Stimul	NULL
P	NULL
y	NULL
$	NULL
Stimulant	NULL
8	NULL
§	NULL
4	NULL
E	NULL
es	NULL
DNA	NULL
2	NULL
<	NULL
z	NULL
<	NULL
58	NULL
&	NULL
(	NULL
9	NULL
&	NULL
E	NULL
1	NULL
2	NULL
3	NULL
-	NULL
4	NULL
5	NULL
-	NULL
6	NULL
10	NULL
20	NULL
030	NULL
4	NULL
5	NULL
6	NULL
e	NULL
3	NULL
4	NULL
e	NULL
=	NULL
witg	NULL
-	NULL
og	NULL
c	NULL
~	NULL
@	NULL
wubuw	NULL
c_	NULL
Hom	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Augmentation	NULL
of	NULL
binding	NULL
activity	NULL
for	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
in	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
,	NULL
PHA	NULL
,	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
.	NULL

All	NULL
the	NULL
protein	NULL
binding	NULL
elements	NULL
are	NULL
underlined	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
five	NULL
separate	NULL
experiments	NULL
.	NULL

A	NULL
,	NULL
0.2	NULL
ng	NULL
of	NULL
labeled	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
-307	NULL
GTGAGCTGAGTCAGGCTTCC	NULL
-288	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
prestimulated	NULL
primary	NULL
T	NULL
cells	NULL
incubated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
or	NULL
incubated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
anti-CD3	NULL
(	NULL
OKT3	NULL
)	NULL
antibody	NULL
plus	NULL
IL2	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
anti-CD2	NULL
antibodies	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
PHA	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
C.	NULL
B	NULL
,	NULL
the	NULL
-307	NULL
to	NULL
-288	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extract	NULL
prepared	NULL
from	NULL
prestimulated	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
2-6	NULL
)	NULL
of	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
competitor	NULL
DNA	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
no	NULL
competitor	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
AP-1	NULL
(	NULL
-307	NULL
to	NULL
-288	NULL
)	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
NF-IL3A	NULL
oligonucleotide	NULL
(	NULL
-161	NULL
TCATGGATGAATAATTACGT	NULL
-142	NULL
)	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
AP-2	NULL
and	NULL
Sp1	NULL
oligonucleotide	NULL
(	NULL
-98	NULL
CCGACGCCTGCCCCACACCACCACCTCCCCCCGCCTTGCC	NULL
-59	NULL
)	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
CK1	NULL
and	NULL
CK2	NULL
oligonucleotide	NULL
(	NULL
-126	NULL
GAGGTTCCATGTCAGATAAA	NULL
-107	NULL
)	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
salmon	NULL
sperm	NULL
DNA	NULL
.	NULL

C	NULL
,	NULL
the	NULL
labeled	NULL
-307	NULL
to	NULL
-288	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
prestimulated	NULL
primary	NULL
T	NULL
cells	NULL
incubated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
or	NULL
incubated	NULL
for	NULL
16	NULL
h	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
plus	NULL
IL2	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
anti-CD2	NULL
antibodies	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

CD2-induced	NULL
AP-1	NULL
binding	NULL
activity	NULL
is	NULL
selectively	NULL
diminished	NULL
after	NULL
16	NULL
h	NULL
of	NULL
stimulation	NULL
.	NULL

since	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
DNA-protein	NULL
complex	NULL
diminished	NULL
markedly	NULL
when	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
cells	NULL
stimulated	NULL
for	NULL
16	NULL
h	NULL
rather	NULL
than	NULL
3	NULL
h	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
A	NULL
and	NULL
C	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
prolonged	NULL
T	NULL
cell	NULL
activation	NULL
by	NULL
PHA	NULL
plus	NULL
PMA	NULL
did	NULL
not	NULL
affect	NULL
putative	NULL
AP-1	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
IL3	NULL
mRNA	NULL
expression	NULL
in	NULL
prestimulated	NULL
T	NULL
cells	NULL
were	NULL
thus	NULL
quite	NULL
similar	NULL
to	NULL
the	NULL
pattern	NULL
seen	NULL
following	NULL
induction	NULL
of	NULL
AP-1	NULL
binding	NULL
activity	NULL
:	NULL
anti-CD2	NULL
mediated	NULL
augmentation	NULL
was	NULL
transient	NULL
whereas	NULL
the	NULL
effects	NULL
of	NULL
PHA	NULL
plus	NULL
PMA	NULL
stimulation	NULL
were	NULL
sustained	NULL
(	NULL
compare	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
3	NULL
,	NULL
A-C	NULL
)	NULL
.	NULL

The	NULL
transient	NULL
nature	NULL
of	NULL
CD2	NULL
stimulation	NULL
likely	NULL
reflects	NULL
rapid	NULL
diacylglycerol	NULL
turnover	NULL
and	NULL
consequently	NULL
transient	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
,	NULL
versus	NULL
the	NULL
the	NULL
more	NULL
sustained	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
seen	NULL
after	NULL
direct	NULL
stimulation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
by	NULL
PMA	NULL
(	NULL
35	NULL
)	NULL
.	NULL

An	NULL
oligonucleotide	NULL
(	NULL
designated	NULL
NF-IL3A	NULL
)	NULL
containing	NULL
DNA	NULL
elements	NULL
related	NULL
to	NULL
consensus	NULL
binding	NULL
sequences	NULL
for	NULL
AP-1	NULL
and	NULL
Oct	NULL
(	NULL
-161	NULL
to	NULL
-142	NULL
)	NULL
was	NULL
next	NULL
assessed	NULL
in	NULL
gel	NULL
retardation	NULL
assays	NULL
.	NULL

This	NULL
oligomer	NULL
produced	NULL
a	NULL
specific	NULL
single	NULL
band	NULL
(	NULL
designated	NULL
NF-IL3A-1	NULL
)	NULL
when	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
prestimulated	NULL
(	NULL
noninduced	NULL
)	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
whether	NULL
extracts	NULL
were	NULL
derived	NULL
from	NULL
resting	NULL
or	NULL
from	NULL
prestimulated	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Activation	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
,	NULL
PHA	NULL
alone	NULL
,	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
for	NULL
3	NULL
h	NULL
did	NULL
not	NULL
increase	NULL
the	NULL
intensity	NULL
of	NULL
band	NULL
NF-IL3A-1	NULL
but	NULL
did	NULL
induce	NULL
a	NULL
second	NULL
band	NULL
(	NULL
NF-IL3A-2	NULL
)	NULL
migrating	NULL
a	NULL
little	NULL
faster	NULL
than	NULL
band	NULL
NF-IL3A-1	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

Although	NULL
band	NULL
NF-IL3A-1	NULL
was	NULL
also	NULL
observed	NULL
following	NULL
incubation	NULL
with	NULL
anti-CD3	NULL
plus	NULL
IL2	NULL
or	NULL
with	NULL
PMA	NULL
alone	NULL
,	NULL
no	NULL
inducible	NULL
band	NULL
(	NULL
i.e	NULL
.	NULL

NF-IL3A-2	NULL
)	NULL
was	NULL
detected	NULL
following	NULL
incubation	NULL
with	NULL
these	NULL
e..tracts	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Both	NULL
NF-IL3A-1	NULL
and	NULL
NF-IL3A-2	NULL
resulted	NULL
from	NULL
sequence-specific	NULL
binding	NULL
:	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
(	NULL
-161	NULL
to	NULL
-142	NULL
)	NULL
was	NULL
able	NULL
to	NULL
completely	NULL
displace	NULL
both	NULL
sets	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
labeled	NULL
oligomer	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Additional	NULL
competitors	NULL
like	NULL
oligonucleotides	NULL
containing	NULL
AP-2	NULL
and	NULL
Sp1	NULL
binding	NULL
elements	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
CK1	NULL
and	NULL
CK2	NULL
elements	NULL
or	NULL
salmon	NULL
sperm	NULL
DNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
either	NULL
protein-DNA	NULL
complex	NULL
.	NULL

Of	NULL
interest	NULL
,	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
AP-1	NULL
binding	NULL
activity	NULL
displaced	NULL
band	NULL
NF-IL3A-2	NULL
but	NULL
not	NULL
band	NULL
NF-IL3A-1	NULL
,	NULL
suggesting	NULL
that	NULL
NF-IL3A	NULL
may	NULL
interact	NULL
in	NULL
part	NULL
with	NULL
AP-1-binding	NULL
proteins	NULL
.	NULL

The	NULL
inducible	NULL
NF-IL3A-2	NULL
complex	NULL
was	NULL
no	NULL
longer	NULL
detectable	NULL
in	NULL
extracts	NULL
from	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
for	NULL
16	NULL
h	NULL
,	NULL
rather	NULL
than	NULL
3	NULL
h	NULL
,	NULL
whereas	NULL
NF-IL3A-2	NULL
was	NULL
still	NULL
easily	NULL
detectable	NULL
following	NULL
incubation	NULL
with	NULL
extracts	NULL
derived	NULL
from	NULL
T	NULL
cells	NULL
stimu-	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
(	NULL
A	NULL
)	NULL
2	NULL
(	NULL
B	NULL
)	NULL
<	NULL
3	NULL
g	NULL
3	NULL
a=	NULL
&	NULL
imul	NULL
o	NULL
p	NULL
if	NULL
«	NULL
g	NULL
P3	NULL
Competitor	NULL
Stimulant	NULL
3	NULL
é	NULL
E	NULL
E	NULL
Z	NULL
E	NULL
DNA	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
NF-IL3A-1	NULL
-	NULL
CMa	NULL
©	NULL
mk	NULL
NF-IL3A-1	NULL
neusas	NULL
.	NULL

(	NULL
e	NULL
if	NULL
“	NULL
$	NULL
-	NULL
NF-IL3A-2	NULL
gs	NULL
``	NULL
*s	NULL
ca	NULL
6303	NULL
(	NULL
C	NULL
.a	NULL
-_	NULL
)	NULL
ie	NULL
a	NULL
&	NULL
3	NULL
g	NULL
§	NULL
3	NULL
te	NULL
2	NULL
B	NULL
&	NULL
4	NULL
<	NULL
rg	NULL
€8	NULL
e	NULL
o	NULL
%	NULL
%	NULL
2	NULL
5	NULL
t.	NULL
g.	NULL
g.	NULL
Stimulant	NULL
S	NULL
z	NULL
3	NULL
h	NULL
6	NULL
2	NULL
.	NULL

%	NULL
<	NULL
lis	NULL
O	NULL
<	NULL
A	NULL
.	NULL

1	NULL
2	NULL
3	NULL
4	NULL
1	NULL
.	NULL

3	NULL
4	NULL
~	NULL
u	NULL
NF-IL3A-1	NULL
-	NULL
Tuts	NULL
NF-IL3A-2	NULL
-	NULL
*	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Mobility	NULL
shift	NULL
analysis	NULL
with	NULL
the	NULL
NF-IL3A	NULL
oligonucleotide	NULL
:	NULL
demonstration	NULL
of	NULL
NF-IL3A-1	NULL
and	NULL
NF-IL3A-2	NULL
protein-DNA	NULL
complexes	NULL
.	NULL

A	NULL
,	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
NF-IL3A	NULL
sequence	NULL
(	NULL
-161	NULL
TCATGGATGAATAATTACGT	NULL
-142	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
T	NULL
cells	NULL
incubated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
incubated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
plus	NULL
IL2	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
anti-CD2	NULL
antibodies	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
PHA	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

The	NULL
more	NULL
slowly	NULL
migrating	NULL
DNA-protein	NULL
complex	NULL
and	NULL
the	NULL
more	NULL
rapidly	NULL
migrating	NULL
complex	NULL
are	NULL
indicated	NULL
by	NULL
NF-IL3A-1	NULL
and	NULL
NF-IL3A-2	NULL
,	NULL
respectively	NULL
.	NULL

All	NULL
results	NULL
shown	NULL
here	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
to	NULL
five	NULL
separate	NULL
experiments	NULL
.	NULL

B	NULL
,	NULL
competition	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
no	NULL
competitor	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
NF-IL3A	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
AP-1	NULL
oligonucleotide	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
AP-2	NULL
and	NULL
SP1	NULL
oligonucleotide	NULL
.	NULL

C	NULL
,	NULL
the	NULL
NF-IL3A	NULL
oligomer	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
T	NULL
cells	NULL
incubated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
or	NULL
incubated	NULL
for	NULL
16	NULL
h	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
plus	NULL
IL2	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
anti-CD2	NULL
antibodies	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

CD2-induced	NULL
NF-IL3A-2	NULL
binding	NULL
is	NULL
selectively	NULL
reduced	NULL
after	NULL
16	NULL
h	NULL
of	NULL
stimulation	NULL
.	NULL

lated	NULL
for	NULL
16	NULL
h	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

The	NULL
relatively	NULL
transient	NULL
nature	NULL
of	NULL
CD2-mediated	NULL
augmentation	NULL
of	NULL
NF-IL3A	NULL
binding	NULL
activity	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
AP-1	NULL
oligomer	NULL
binding	NULL
assays	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
was	NULL
next	NULL
performed	NULL
with	NULL
extracts	NULL
from	NULL
resting	NULL
and	NULL
activated	NULL
primary	NULL
T	NULL
cells	NULL
;	NULL
results	NULL
were	NULL
in	NULL
accord	NULL
with	NULL
the	NULL
mapping	NULL
data	NULL
in	NULL
that	NULL
protection	NULL
was	NULL
observed	NULL
at	NULL
both	NULL
-307	NULL
to	NULL
-288	NULL
and	NULL
at	NULL
-155	NULL
to	NULL
-147	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
activated	NULL
T	NULL
cell	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Protection	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
any	NULL
other	NULL
region	NULL
from	NULL
-313	NULL
to	NULL
+47	NULL
.	NULL

Construct	NULL
-59	NULL
consistently	NULL
produced	NULL
zero	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
compared	NULL
to	NULL
all	NULL
other	NULL
uninduced	NULL
constructs	NULL
whereas	NULL
construct	NULL
-107	NULL
was	NULL
capable	NULL
of	NULL
driving	NULL
the	NULL
low	NULL
level	NULL
of	NULL
constitutive	NULL
promoter	NULL
activity	NULL
noted	NULL
in	NULL
all	NULL
the	NULL
other	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Mobility	NULL
shift	NULL
assays	NULL
were	NULL
thus	NULL
next	NULL
performed	NULL
with	NULL
an	NULL
oligonucleotide	NULL
spanning	NULL
bases	NULL
-98	NULL
to	NULL
-59	NULL
.	NULL

Two	NULL
constitutive	NULL
noninducible	NULL
sequence-specific	NULL
complexes	NULL
were	NULL
observed	NULL
following	NULL
incubation	NULL
of	NULL
the	NULL
labeled	NULL
oligomer	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
resting	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

AP-1-	NULL
and	NULL
Octamer-binding	NULL
Proteins	NULL
Interact	NULL
with	NULL
Functionally	NULL
Important	NULL
Regulatory	NULL
Sequences	NULL
of	NULL
the	NULL
IL3	NULL
Pro-moter-Studies	NULL
were	NULL
next	NULL
performed	NULL
to	NULL
characterize	NULL
the	NULL
DNA-binding	NULL
proteins	NULL
which	NULL
specifically	NULL
interact	NULL
with	NULL
the	NULL
NF-IL3A	NULL
(	NULL
-161	NULL
to	NULL
-142	NULL
)	NULL
and	NULL
the	NULL
AP-1	NULL
(	NULL
-307	NULL
to	NULL
-288	NULL
)	NULL
sites	NULL
of	NULL
the	NULL
IL3	NULL
promoter	NULL
.	NULL

Gel	NULL
retardation	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
antibodies	NULL
specific	NULL
to	NULL
human	NULL
c-Jun	NULL
,	NULL
c-Fos	NULL
,	NULL
Oct-1	NULL
,	NULL
and	NULL
Oct-2	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

These	NULL
studies	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
either	NULL
Jurkat	NULL
cells	NULL
or	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
first	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
activated	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
and	NULL
incubated	NULL
with	NULL
the	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
antibodies	NULL
.	NULL

Antisera	NULL
to	NULL
either	NULL
c-Jun	NULL
or	NULL
c-Fos	NULL
were	NULL
capable	NULL
of	NULL
inhibiting	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
single	NULL
specific	NULL
complex	NULL
(	NULL
band	NULL
C	NULL
)	NULL
by	NULL
90	NULL
and	NULL
70	NULL
%	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
as	NULL
assessed	NULL
by	NULL
laser	NULL
densitometry	NULL
.	NULL

Anti-Jun	NULL
antibody	NULL
also	NULL
resulted	NULL
in	NULL
further	NULL
retardation	NULL
of	NULL
the	NULL
DNA-protein	NULL
complex	NULL
(	NULL
see	NULL
S	NULL
on	NULL
lanes	NULL
2	NULL
and	NULL
b	NULL
)	NULL
(	NULL
lanes	NULL
a	NULL
and	NULL
b	NULL
are	NULL
from	NULL
a	NULL
duplicate	NULL
experiment	NULL
and	NULL
correspond	NULL
to	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

However	NULL
,	NULL
antisera	NULL
to	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
as	NULL
well	NULL
as	NULL
control	NULL
rabbit	NULL
serum	NULL
had	NULL
no	NULL
discernable	NULL
effect	NULL
on	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
putative	NULL
AP-1	NULL
binding	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
4-6	NULL
)	NULL
.	NULL

The	NULL
identical	NULL
Jurkat	NULL
extracts	NULL
were	NULL
next	NULL
incubated	NULL
with	NULL
the	NULL
NF-IL3A	NULL
oligonucleotide	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
antibodies	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
bands	NULL
NF-IL3A-1	NULL
and	NULL
NF-IL3A-2	NULL
(	NULL
previously	NULL
seen	NULL
in	NULL
mobility	NULL
shift	NULL
assays	NULL
with	NULL
primary	NULL
T	NULL
cells	NULL
)	NULL
a	NULL
new	NULL
band	NULL
(	NULL
NF-IL3A-3	NULL
)	NULL
was	NULL
observed	NULL
following	NULL
incubation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Like	NULL
NF-IL3A-1	NULL
,	NULL
NF-IL3A-3	NULL
activity	NULL
was	NULL
not	NULL
inducible	NULL
,	NULL
as	NULL
it	NULL
was	NULL
observed	NULL
without	NULL
alteration	NULL
in	NULL
intensity	NULL
in	NULL
extracts	NULL
from	NULL
both	NULL
resting	NULL
and	NULL
stimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
,	NULL
NF-IL3A-2	NULL
was	NULL
strongly	NULL
induced	NULL
following	NULL
oligomer	NULL
incubation	NULL
with	NULL
extracts	NULL
from	NULL
activated	NULL
Jurkat	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
three	NULL
Jurkat	NULL
NF-IL3A	NULL
complexes	NULL
demonstrated	NULL
unique	NULL
and	NULL
specific	NULL
responses	NULL
to	NULL
antibody	NULL
in	NULL
mobility	NULL
shift	NULL
6304	NULL
a	NULL
S	NULL
t	NULL
>	NULL
-	NULL
No	NULL
extract	NULL
1	NULL
-307	NULL
>	NULL
48g	NULL
AP	NULL
|	NULL
-155	NULL
{	NULL
37	NULL
NHHL3A	NULL
1000	NULL
%	NULL
)	NULL
)	NULL
p	NULL
I	NULL
|	NULL
@	NULL
*	NULL
1~	NULL
ue	NULL
|	NULL
:	NULL
;	NULL
*	NULL
%	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Two	NULL
5	NULL
'	NULL
regions	NULL
(	NULL
-307	NULL
to	NULL
-288	NULL
and	NULL
-155	NULL
to	NULL
-147	NULL
)	NULL
are	NULL
protected	NULL
from	NULL
DNase	NULL
I	NULL
by	NULL
primary	NULL
T	NULL
cell	NULL
nuclear	NULL
ex-tracts	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
with	NULL
1	NULL
ng	NULL
of	NULL
a	NULL
5	NULL
fragment	NULL
from	NULL
-313	NULL
to	NULL
+47	NULL
of	NULL
the	NULL
IL3	NULL
promoter	NULL
.	NULL

The	NULL
fragment	NULL
had	NULL
been	NULL
end-labeled	NULL
at	NULL
the	NULL
+47	NULL
terminus	NULL
.	NULL

The	NULL
DNA-protein	NULL
mixture	NULL
was	NULL
subsequently	NULL
subjected	NULL
to	NULL
digestion	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
DNase	NULL
I	NULL
for	NULL
1	NULL
min	NULL
and	NULL
extracted	NULL
with	NULL
phenol	NULL
prior	NULL
to	NULL
fractionation	NULL
in	NULL
a	NULL
7.5	NULL
M	NULL
urea-6	NULL
%	NULL
acrylamide	NULL
gel	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
¢X174/Haelll	NULL
molecular	NULL
mass	NULL
markers	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
DNA	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
nuclear	NULL
extract	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
DNA	NULL
plus	NULL
20	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
prestimulated	NULL
primary	NULL
T	NULL
cells	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
DNA	NULL
plus	NULL
50	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
prestimulated	NULL
primary	NULL
T	NULL
cells	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
DNA	NULL
plus	NULL
50	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
prestimulated	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
.	NULL

assays	NULL
.	NULL

NF-IL3A-2	NULL
was	NULL
specifically	NULL
inhibited	NULL
by	NULL
antibody	NULL
to	NULL
c-Jun	NULL
(	NULL
100	NULL
%	NULL
inhibition	NULL
)	NULL
and	NULL
c-Fos	NULL
(	NULL
90	NULL
%	NULL
inhibition	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
,	NULL
whereas	NULL
NF-IL3A-1	NULL
was	NULL
completely	NULL
inhibited	NULL
by	NULL
antibodies	NULL
to	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
with	NULL
no	NULL
observed	NULL
inhibition	NULL
following	NULL
incubation	NULL
with	NULL
antibodies	NULL
to	NULL
c-Jun	NULL
or	NULL
c-Fos	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
)	NULL
.	NULL

Formation	NULL
of	NULL
band	NULL
NF-IL3A-3	NULL
was	NULL
inhibited	NULL
only	NULL
by	NULL
antibody	NULL
to	NULL
Oct-2	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
.	NULL

Antibody	NULL
to	NULL
c-Jun	NULL
also	NULL
produced	NULL
a	NULL
supershifted	NULL
NF-IL3A-2	NULL
band	NULL
(	NULL
see	NULL
lanes	NULL
8	NULL
and	NULL
d	NULL
)	NULL
(	NULL
lanes	NULL
c	NULL
and	NULL
d	NULL
are	NULL
from	NULL
a	NULL
duplicate	NULL
experiment	NULL
and	NULL
correspond	NULL
to	NULL
lames	NULL
7	NULL
and	NULL
8	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Immunodepletion	NULL
experiments	NULL
were	NULL
also	NULL
performed	NULL
wherein	NULL
nuclear	NULL
extracts	NULL
were	NULL
first	NULL
incubated	NULL
with	NULL
antibody	NULL
for	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
labeled	NULL
AP-1	NULL
or	NULL
NF-IL3A	NULL
probe	NULL
;	NULL
results	NULL
were	NULL
entirely	NULL
consistent	NULL
with	NULL
the	NULL
supershift	NULL
assays	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
above	NULL
data	NULL
indicate	NULL
that	NULL
AP-1-	NULL
and	NULL
octamer-binding	NULL
nuclear	NULL
proteins	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
DNA-protein	NULL
complexes	NULL
with	NULL
functionally	NULL
important	NULL
regions	NULL
of	NULL
the	NULL
IL3	NULL
promoter	NULL
in	NULL
unstimulated	NULL
and	NULL
stimulated	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
next	NULL
prepared	NULL
from	NULL
primary	NULL
T	NULL
cells	NULL
activated	NULL
either	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
or	NULL
with	NULL
anti-CD2	NULL
anti-bodies	NULL
;	NULL
these	NULL
extracts	NULL
were	NULL
examined	NULL
in	NULL
mobility	NULL
shift	NULL
assays	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
antibody	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
observed	NULL
after	NULL
either	NULL
CD2	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
activation	NULL
.	NULL

The	NULL
inducible	NULL
DNA-protein	NULL
complex	NULL
formed	NULL
after	NULL
incubation	NULL
with	NULL
the	NULL
AP-1-containing	NULL
oligomer	NULL
was	NULL
specifically	NULL
displaced	NULL
by	NULL
antibody	NULL
to	NULL
c-Jun	NULL
(	NULL
80	NULL
%	NULL
inhibition	NULL
)	NULL
and	NULL
antibody	NULL
to	NULL
c-Fos	NULL
(	NULL
90	NULL
%	NULL
inhibition	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

A	NULL
supershifted	NULL
band	NULL
was	NULL
again	NULL
produced	NULL
with	NULL
c-Jun	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
2	NULL
,	NULL
S	NULL
)	NULL
.	NULL

Antibodies	NULL
to	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
AP-1	NULL
protein-DNA	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
activated	NULL
primary	NULL
T	NULL
cells	NULL
were	NULL
next	NULL
incubated	NULL
with	NULL
the	NULL
NF-IL3A	NULL
oligonucleotide	NULL
.	NULL

Antibodies	NULL
to	NULL
c-Jun	NULL
and	NULL
c-Fos	NULL
inhibited	NULL
formation	NULL
of	NULL
the	NULL
inducible	NULL
band	NULL
NF-IL3A-2	NULL
by	NULL
90	NULL
and	NULL
80	NULL
%	NULL
,	NULL
respectively	NULL
;	NULL
antibodies	NULL
to	NULL
Oct-1	NULL
or	NULL
Oct-2	NULL
as	NULL
well	NULL
as	NULL
rabbit	NULL
serum	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
NF-IL3A-2	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
7-12	NULL
)	NULL
.	NULL

The	NULL
constitutive	NULL
band	NULL
NF-IL3A-1	NULL
was	NULL
almost	NULL
completely	NULL
displaced	NULL
by	NULL
antibodies	NULL
to	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
antibodies	NULL
to	NULL
c-Jun	NULL
or	NULL
c-Fos	NULL
or	NULL
rabbit	NULL
serum	NULL
.	NULL

The	NULL
above	NULL
data	NULL
indicate	NULL
that	NULL
AP-1-	NULL
and	NULL
octamer-binding	NULL
nuclear	NULL
proteins	NULL
from	NULL
primary	NULL
T	NULL
cells	NULL
specifically	NULL
interact	NULL
with	NULL
functionally	NULL
important	NULL
sequences	NULL
from	NULL
the	NULL
IL3	NULL
promoter	NULL
.	NULL

UV	NULL
cross-linking	NULL
studies	NULL
were	NULL
next	NULL
performed	NULL
to	NULL
more	NULL
fully	NULL
characterize	NULL
the	NULL
proteins	NULL
binding	NULL
to	NULL
specific	NULL
sequences	NULL
within	NULL
the	NULL
IL3	NULL
promoter	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
CD2-activated	NULL
primary	NULL
T	NULL
cells	NULL
and	NULL
incubated	NULL
with	NULL
either	NULL
the	NULL
oligomer	NULL
containing	NULL
the	NULL
AP-1	NULL
motif	NULL
or	NULL
the	NULL
NF-IL3A	NULL
oligonucleotide	NULL
prior	NULL
to	NULL
irradiation	NULL
and	NULL
gel	NULL
electrophoresis	NULL
.	NULL

A	NULL
single	NULL
protein-DNA	NULL
adduct	NULL
was	NULL
observed	NULL
,	NULL
after	NULL
incubation	NULL
with	NULL
the	NULL
probe	NULL
containing	NULL
the	NULL
AP-1	NULL
motif	NULL
,	NULL
which	NULL
migrated	NULL
with	NULL
an	NULL
apparent	NULL
molecular	NULL
mass	NULL
of	NULL
39	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
;	NULL
the	NULL
size	NULL
of	NULL
this	NULL
adduct	NULL
is	NULL
consistent	NULL
with	NULL
that	NULL
of	NULL
human	NULL
c-Jun	NULL
(	NULL
39	NULL
kDa	NULL
)	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
adduct	NULL
was	NULL
almost	NULL
completely	NULL
displaced	NULL
by	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

When	NULL
the	NULL
NF-IL3A	NULL
probe	NULL
was	NULL
used	NULL
for	NULL
UV	NULL
cross-linking	NULL
,	NULL
a	NULL
broad	NULL
band	NULL
was	NULL
observed	NULL
ranging	NULL
between	NULL
39	NULL
and	NULL
50	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
;	NULL
short	NULL
exposure	NULL
of	NULL
the	NULL
autoradiogram	NULL
resolved	NULL
this	NULL
broad	NULL
band	NULL
into	NULL
three	NULL
separate	NULL
adducts	NULL
ranging	NULL
from	NULL
39	NULL
to	NULL
50	NULL
kDa	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

An	NULL
additional	NULL
band	NULL
was	NULL
also	NULL
observed	NULL
which	NULL
migrated	NULL
with	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
about	NULL
95	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
which	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
reported	NULL
molecular	NULL
mass	NULL
of	NULL
Oct-1	NULL
(	NULL
90-100	NULL
kDa	NULL
)	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Prior	NULL
incubation	NULL
of	NULL
extract	NULL
with	NULL
anti-Oct	NULL
antibody	NULL
before	NULL
cross-linking	NULL
specifically	NULL
abrogated	NULL
the	NULL
95-kDa	NULL
adduct	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
NF-IL3A	NULL
adducts	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analyses	NULL
were	NULL
next	NULL
combined	NULL
with	NULL
gel	NULL
retardation	NULL
assays	NULL
to	NULL
provide	NULL
further	NULL
evidence	NULL
for	NULL
the	NULL
identity	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
and	NULL
NF-IL3A	NULL
sites	NULL
.	NULL

Varying	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
excised	NULL
from	NULL
the	NULL
wet	NULL
retardation	NULL
gel	NULL
and	NULL
subjected	NULL
to	NULL
Western	NULL
blot	NULL
analysis	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

A	NULL
protein	NULL
band	NULL
migrating	NULL
at	NULL
a	NULL
molecular	NULL
mass	NULL
of	NULL
39	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
was	NULL
observed	NULL
with	NULL
anti-c-Jun	NULL
antibody	NULL
for	NULL
nuclear	NULL
extracts	NULL
loaded	NULL
directly	NULL
onto	NULL
the	NULL
SDS-polyacrylamide	NULL
gel	NULL
(	NULL
positive	NULL
control	NULL
)	NULL
.	NULL

An	NULL
identical	NULL
band	NULL
was	NULL
detected	NULL
by	NULL
anti-c-Jun	NULL
antibody	NULL
following	NULL
excision	NULL
of	NULL
either	NULL
the	NULL
AP-1	NULL
complex	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
the	NULL
NF-IL3A-2	NULL
complex	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

No	NULL
band	NULL
was	NULL
observed	NULL
in	NULL
a	NULL
corresponding	NULL
gel	NULL
slice	NULL
that	NULL
contained	NULL
only	NULL
labeled	NULL
NF-IL3A	NULL
probe	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
6305	NULL
(	NULL
A	NULL
)	NULL
Probe	NULL
AP-1	NULL
/	NULL
NF-IL3A	NULL
Antibody	NULL
none	NULL
c-Jun	NULL
c-Fos	NULL
Oct-l	NULL
Oct-2	NULL
Rabbit	NULL
none	NULL
c-Jun	NULL
c-Fos	NULL
Oct-1	NULL
Oct-2	NULL
Rabbit	NULL
Against	NULL
Serum	NULL
Serum	NULL
Io	NULL
_	NULL
2	NULL
0	NULL
3	NULL
0	NULL
400	NULL
500	NULL
0600	NULL
70	NULL
8	NULL
%	NULL
9	NULL
100	NULL
I1	NULL
2	NULL
a	NULL
b	NULL
c	NULL
_	NULL
_d	NULL
Origin	NULL
-	NULL
&	NULL
..®	NULL
%	NULL
R	NULL
M	NULL
§	NULL
:	NULL
.	NULL

A	NULL
«	NULL
e	NULL
.	NULL

%	NULL
-	NULL
NF-IL3A-1	NULL
-	NULL
NF-IL3A-2	NULL
<	NULL
be	NULL
-	NULL
NF-IL3A-3	NULL
(	NULL
B	NULL
)	NULL
Probe	NULL
AP-1	NULL
/	NULL
NF-4L3A	NULL
Antibody	NULL
none	NULL
c-Jun	NULL
c-Fos	NULL
Oct-1	NULL
Oct-2	NULL
Rabbit	NULL
none	NULL
c-Jun	NULL
c-Fos	NULL
Oct-1	NULL
Oct-2	NULL
Rabbit	NULL
Against	NULL
Serum	NULL
Serum	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
(	NULL
4	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
Onsgm	NULL
-	NULL
'	NULL
”	NULL
Fa	NULL
%	NULL
-	NULL
NF-IL3A-1	NULL
w	NULL
w	NULL
a	NULL
-	NULL
NF4L3A-2	NULL
FiG	NULL
.	NULL

6	NULL
.	NULL

Anti-c-Jun	NULL
and	NULL
anti-c-Fos	NULL
antibodies	NULL
specifically	NULL
inhibit	NULL
AP-1	NULL
and	NULL
NF-IL3A-2	NULL
binding	NULL
activities	NULL
whereas	NULL
anti-Oct-1	NULL
and	NULL
Oct-2	NULL
antibodies	NULL
inhibit	NULL
NF-IL3A-1	NULL
and	NULL
NF-IL3A-3	NULL
binding	NULL
activities	NULL
.	NULL

A	NULL
,	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
activated	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
for	NULL
3	NULL
h	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
either	NULL
the	NULL
-307	NULL
to	NULL
-288	NULL
AP-1-containing	NULL
oligomer	NULL
(	NULL
lanes	NULL
1-6	NULL
)	NULL
or	NULL
with	NULL
the	NULL
-161	NULL
to	NULL
-142	NULL
NF-IL3A	NULL
oligomer	NULL
(	NULL
lanes	NULL
7-12	NULL
)	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
in	NULL
either	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
1	NULL
ul	NULL
of	NULL
the	NULL
respective	NULL
antibody	NULL
:	NULL
lanes	NULL
1	NULL
and	NULL
7	NULL
,	NULL
no	NULL
antibody	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
,	NULL
anti-c-Jun	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
9	NULL
,	NULL
anti-c-Fos	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
10	NULL
,	NULL
anti-Oct-1	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
11	NULL
,	NULL
anti-Oct-2	NULL
;	NULL
lanes	NULL
6	NULL
and	NULL
12	NULL
,	NULL
rabbit	NULL
serum	NULL
(	NULL
GIBCO	NULL
)	NULL
.	NULL

A	NULL
supershifted	NULL
band	NULL
is	NULL
indicated	NULL
by	NULL
S.	NULL
The	NULL
AP-1-DNA	NULL
complex	NULL
is	NULL
indicated	NULL
by	NULL
C.	NULL
Similar	NULL
results	NULL
were	NULL
seen	NULL
in	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

The	NULL
slowly	NULL
migrating	NULL
faint	NULL
band	NULL
seen	NULL
after	NULL
treatment	NULL
with	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
antiserum	NULL
or	NULL
with	NULL
rabbit	NULL
antiserum	NULL
results	NULL
from	NULL
nonspecific	NULL
interactions	NULL
between	NULL
the	NULL
oligomer	NULL
and	NULL
proteins	NULL
present	NULL
in	NULL
the	NULL
sera	NULL
(	NULL
Dr.	NULL
Philip	NULL
Sharp	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

Lanes	NULL
a	NULL
,	NULL
b	NULL
,	NULL
c	NULL
,	NULL
and	NULL
d	NULL
are	NULL
derived	NULL
from	NULL
a	NULL
duplicate	NULL
experiment	NULL
and	NULL
correspond	NULL
to	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
,	NULL
respectively	NULL
.	NULL

B	NULL
,	NULL
Mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
with	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
prestimulated	NULL
primary	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
for	NULL
3	NULL
h	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
the	NULL
AP-1-containing	NULL
oligomer	NULL
(	NULL
lanes	NULL
1-6	NULL
)	NULL
or	NULL
the	NULL
NF-IL3A	NULL
oligomer	NULL
(	NULL
lanes	NULL
7-12	NULL
)	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
1	NULL
ul	NULL
of	NULL
the	NULL
respective	NULL
antibody	NULL
:	NULL
lanes	NULL
1	NULL
and	NULL
7	NULL
,	NULL
no	NULL
antibody	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
,	NULL
anti-c-Jun	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
9	NULL
,	NULL
anti-c-Fos	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
10	NULL
,	NULL
anti-Oct-1	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
11	NULL
,	NULL
anti-Oct-2	NULL
;	NULL
lanes	NULL
6	NULL
and	NULL
12	NULL
,	NULL
rabbit	NULL
serum	NULL
(	NULL
GIBCO	NULL
)	NULL
.	NULL

The	NULL
supershifted	NULL
band	NULL
is	NULL
indicated	NULL
by	NULL
S.	NULL
Similar	NULL
results	NULL
were	NULL
seen	NULL
in	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

or	NULL
from	NULL
a	NULL
control	NULL
slice	NULL
of	NULL
the	NULL
retardation	NULL
gel	NULL
containing	NULL
extract	NULL
alone	NULL
;	NULL
this	NULL
gel	NULL
slice	NULL
was	NULL
excised	NULL
from	NULL
a	NULL
position	NULL
immediately	NULL
adjacent	NULL
to	NULL
the	NULL
NF-IL3A-2	NULL
DNA-protein	NULL
complex	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

In	NULL
similar	NULL
experiments	NULL
,	NULL
two	NULL
bands	NULL
were	NULL
detected	NULL
,	NULL
migrating	NULL
at	NULL
95	NULL
(	NULL
band	NULL
a	NULL
)	NULL
and	NULL
76	NULL
(	NULL
band	NULL
b	NULL
)	NULL
kDa	NULL
,	NULL
by	NULL
anti-Oct-1	NULL
antibody	NULL
following	NULL
excision	NULL
of	NULL
the	NULL
NF-IL3A-1	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

No	NULL
band	NULL
was	NULL
observed	NULL
with	NULL
anti-Oct-1	NULL
antibody	NULL
in	NULL
a	NULL
corresponding	NULL
gel	NULL
slice	NULL
that	NULL
contained	NULL
only	NULL
labeled	NULL
NF-IL3A	NULL
probe	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
in	NULL
the	NULL
control	NULL
gel	NULL
slice	NULL
containing	NULL
extract	NULL
alone	NULL
and	NULL
taken	NULL
from	NULL
a	NULL
position	NULL
immediately	NULL
adjacent	NULL
to	NULL
the	NULL
NF-IL3A-1	NULL
complex	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
95-kDa	NULL
band	NULL
corresponds	NULL
to	NULL
the	NULL
molecular	NULL
mass	NULL
of	NULL
Oct-1	NULL
and	NULL
is	NULL
identical	NULL
to	NULL
one	NULL
of	NULL
the	NULL
bands	NULL
observed	NULL
following	NULL
UV	NULL
cross-linking	NULL
of	NULL
the	NULL
NF-IL3A	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
76-kDa	NULL
band	NULL
likely	NULL
represents	NULL
a	NULL
partial	NULL
degradation	NULL
product	NULL
of	NULL
Oct-1	NULL
,	NULL
the	NULL
possibility	NULL
that	NULL
it	NULL
is	NULL
another	NULL
protein	NULL
closely	NULL
related	NULL
to	NULL
Oct-1	NULL
can	NULL
not	NULL
be	NULL
entirely	NULL
6306	NULL
(	NULL
A	NULL
)	NULL
Probe	NULL
AP-1	NULL
MW	NULL
(	NULL
kDa	NULL
)	NULL
Competitor	NULL
none	NULL
_	NULL
AP-1	NULL
DNA	NULL
1	NULL
2	NULL
_106	NULL
_80	NULL
_	NULL
49.5	NULL
Adduct-	NULL
«	NULL
32.5	NULL
rx	NULL
$	NULL
.	NULL

Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
(	NULL
B	NULL
)	NULL
Probe	NULL
NF-IL3A	NULL
MW	NULL
(	NULL
kDa	NULL
)	NULL
Competitor	NULL
none	NULL
_	NULL
NF-IL3A	NULL
DNA	NULL
1	NULL
2	NULL
_106	NULL
Adduct	NULL
e	NULL
_so	NULL
_	NULL
49.5	NULL
Adduct-	NULL
.	NULL

32.5	NULL
M4	NULL
$	NULL
]	NULL
a	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

UV	NULL
cross-linking	NULL
performed	NULL
with	NULL
either	NULL
the	NULL
-307	NULL
to	NULL
-288	NULL
AP-1	NULL
containing	NULL
oligomer	NULL
(	NULL
A	NULL
)	NULL
or	NULL
the	NULL
NF-IL3A	NULL
oligomer	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
primary	NULL
T	NULL
cells	NULL
activated	NULL
for	NULL
3	NULL
h	NULL
with	NULL
anti-CD2	NULL
antibodies	NULL
.	NULL

A	NULL
,	NULL
extract-DNA	NULL
probe	NULL
complexes	NULL
were	NULL
irradiated	NULL
for	NULL
60	NULL
min	NULL
and	NULL
size-fractionated	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Lane	NULL
1	NULL
depicts	NULL
labeled	NULL
AP-1	NULL
probe	NULL
without	NULL
addition	NULL
of	NULL
competitor	NULL
and	NULL
lane	NULL
2	NULL
depicts	NULL
AP-1	NULL
probe	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
.	NULL

Molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
in	NULL
kDa	NULL
on	NULL
the	NULL
right	NULL
.	NULL

B	NULL
,	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
resolved	NULL
on	NULL
a	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
slab	NULL
gels	NULL
were	NULL
irradiated	NULL
for	NULL
20	NULL
min	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
excised	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-10	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

Lane	NULL
1	NULL
depicts	NULL
labeled	NULL
NF-IL3A	NULL
probe	NULL
without	NULL
competitor	NULL
,	NULL
and	NULL
lane	NULL
2	NULL
depicts	NULL
NF-IL3A	NULL
probe	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
.	NULL

excluded	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
at	NULL
least	NULL
two	NULL
proteins	NULL
,	NULL
c-Jun	NULL
and	NULL
Oct-1	NULL
,	NULL
bind	NULL
to	NULL
the	NULL
NF-IL3A	NULL
DNA	NULL
motif	NULL
.	NULL

DISCUSSION	NULL
We	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
that	NULL
IL3	NULL
gene	NULL
expression	NULL
is	NULL
regulated	NULL
at	NULL
least	NULL
in	NULL
part	NULL
by	NULL
transcriptional	NULL
activation	NULL
(	NULL
13-15	NULL
)	NULL
.	NULL

The	NULL
relevant	NULL
transcription	NULL
factors	NULL
mediating	NULL
IL3	NULL
gene	NULL
activity	NULL
are	NULL
largely	NULL
unknown	NULL
.	NULL

Previous	NULL
investigations	NULL
of	NULL
the	NULL
mechanisms	NULL
underlying	NULL
IL3	NULL
transcriptional	NULL
regulation	NULL
have	NULL
been	NULL
restricted	NULL
to	NULL
neoplastic	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
Jurkat	NULL
(	NULL
14	NULL
)	NULL
and	NULL
MLA	NULL
144	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
and	NULL
have	NULL
used	NULL
nonphysiologic	NULL
means	NULL
of	NULL
activation	NULL
such	NULL
as	NULL
concanavalin	NULL
A	NULL
or	NULL
PMA	NULL
as	NULL
an	NULL
experimental	NULL
model	NULL
to	NULL
simulate	NULL
events	NULL
occurring	NULL
during	NULL
normal	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

The	NULL
sequelae	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
following	NULL
either	NULL
antigen	NULL
receptor	NULL
stimulation	NULL
or	NULL
stimulation	NULL
with	NULL
lectins	NULL
and	NULL
phorbol	NULL
esters	NULL
differ	NULL
in	NULL
many	NULL
respects	NULL
including	NULL
the	NULL
kinetics	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
(	NULL
36	NULL
)	NULL
and	NULL
activation	NULL
of	NULL
micro-tubule-associated	NULL
protein-2	NULL
(	NULL
MAP-2	NULL
)	NULL
kinase	NULL
(	NULL
37-39	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
T	NULL
cells	NULL
also	NULL
behave	NULL
differently	NULL
following	NULL
activation	NULL
(	NULL
4	NULL
,	NULL
16	NULL
,	NULL
20	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
assessed	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
using	NULL
antibodies	NULL
against	NULL
the	NULL
T	NULL
cell	NULL
specific	NULL
receptors	NULL
CD3	NULL
and	NULL
CD2	NULL
,	NULL
as	NULL
well	NULL
as	NULL
PHA	NULL
plus	NULL
PMA	NULL
,	NULL
to	NULL
activate	NULL
the	NULL
T	NULL
cell	NULL
.	NULL

We	NULL
have	NULL
also	NULL
used	NULL
mobility	NULL
shift	NULL
assays	NULL
,	NULL
Western	NULL
blot	NULL
analysis	NULL
and	NULL
UV	NULL
cross-linking	NULL
studies	NULL
to	NULL
specifically	NULL
identify	NULL
the	NULL
transcription	NULL
factors	NULL
mediating	NULL
the	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
.	NULL

Our	NULL
transfection	NULL
studies	NULL
with	NULL
a	NULL
nested	NULL
series	NULL
of	NULL
IL3	NULL
promoter	NULL
deletion	NULL
mutants	NULL
indicate	NULL
that	NULL
two	NULL
5	NULL
``	NULL
regions	NULL
,	NULL
-313	NULL
to	NULL
-272	NULL
and	NULL
-161	NULL
to	NULL
-126	NULL
,	NULL
are	NULL
especially	NULL
important	NULL
for	NULL
transcriptional	NULL
stimulation	NULL
following	NULL
primary	NULL
T	NULL
cell	NULL
activation	NULL
via	NULL
the	NULL
CD2	NULL
receptor	NULL
or	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
.	NULL

The	NULL
site	NULL
between	NULL
-313	NULL
and	NULL
-272	NULL
appears	NULL
to	NULL
be	NULL
targeted	NULL
by	NULL
inducible	NULL
AP-1	NULL
activity	NULL
through	NULL
the	NULL
consensus	NULL
AP-1	NULL
binding	NULL
element	NULL
(	NULL
-301	NULL
TGAGTCA	NULL
-295	NULL
)	NULL
.	NULL

The	NULL
data	NULL
also	NULL
indicate	NULL
that	NULL
NF-IL3A	NULL
is	NULL
targeted	NULL
by	NULL
at	NULL
least	NULL
two	NULL
transcription	NULL
factors	NULL
,	NULL
an	NULL
inducible	NULL
AP-1	NULL
activity	NULL
and	NULL
a	NULL
constitutively	NULL
expressed	NULL
octamer-binding	NULL
protein	NULL
(	NULL
probably	NULL
Oct-1	NULL
)	NULL
.	NULL

The	NULL
NF-IL3A	NULL
site	NULL
contains	NULL
at	NULL
least	NULL
two	NULL
transcription	NULL
factor	NULL
binding	NULL
elements	NULL
:	NULL
a	NULL
heptanucleotide	NULL
sequence	NULL
(	NULL
-154	NULL
TGAATAA	NULL
-148	NULL
)	NULL
which	NULL
matches	NULL
the	NULL
consensus	NULL
AP-1	NULL
motif	NULL
(	NULL
TGAG	NULL
(	NULL
C	NULL
)	NULL
TCA	NULL
)	NULL
at	NULL
5	NULL
positions	NULL
(	NULL
33	NULL
)	NULL
and	NULL
an	NULL
overlapping	NULL
octanucleotide	NULL
sequence	NULL
(	NULL
-155	NULL
ATGAATAA	NULL
-148	NULL
)	NULL
which	NULL
matches	NULL
the	NULL
consensus	NULL
octamer	NULL
binding	NULL
site	NULL
(	NULL
ATGCAAAT	NULL
)	NULL
at	NULL
5	NULL
positions	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
antibody	NULL
supershift	NULL
assays	NULL
,	NULL
retardation	NULL
and	NULL
Western	NULL
blot	NULL
analyses	NULL
and	NULL
UV	NULL
cross-linking	NULL
studies	NULL
indicate	NULL
that	NULL
the	NULL
inducible	NULL
DNA	NULL
binding	NULL
activity	NULL
observed	NULL
with	NULL
probe	NULL
-307	NULL
to	NULL
-288	NULL
and	NULL
the	NULL
inducible	NULL
NF-IL3A-2	NULL
complex	NULL
observed	NULL
with	NULL
probe	NULL
-161	NULL
to	NULL
-142	NULL
in	NULL
primary	NULL
and	NULL
Jurkat	NULL
T	NULL
cells	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
the	NULL
heterodimeric	NULL
complex	NULL
consisting	NULL
of	NULL
c-Jun	NULL
plus	NULL
c-Fos	NULL
.	NULL

UV	NULL
cross-linking	NULL
did	NULL
not	NULL
reveal	NULL
a	NULL
protein-DNA	NULL
adduct	NULL
at	NULL
55-70	NULL
kDa	NULL
(	NULL
i.e	NULL
.	NULL

consistent	NULL
with	NULL
a	NULL
c-Fos	NULL
DNA	NULL
adduct	NULL
)	NULL
,	NULL
presumably	NULL
because	NULL
the	NULL
c-Fos	NULL
component	NULL
of	NULL
the	NULL
c-Jun/c-Fos	NULL
heterodimer	NULL
does	NULL
not	NULL
always	NULL
bind	NULL
directly	NULL
to	NULL
the	NULL
AP-1	NULL
DNA	NULL
motif	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Of	NULL
interest	NULL
,	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
not	NULL
induced	NULL
in	NULL
pri-	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
(	NULL
A	NULL
)	NULL
»	NULL
€	NULL
a	NULL
2	NULL
fel	NULL
s	NULL
:	NULL
O	NULL
5	NULL
4	NULL
§	NULL
f	NULL
$	NULL
€	NULL
0	NULL
B	NULL
a	NULL
&	NULL
f	NULL
5	NULL
5	NULL
G	NULL
GS	NULL
CE	NULL
Sl	NULL
$	NULL
MW	NULL
(	NULL
kDa	NULL
)	NULL
&	NULL
v-	NULL
pas	NULL
sex	NULL
2	NULL
f	NULL
(	NULL
22	NULL
Lo	NULL
Ce	NULL
1004	NULL
&	NULL
£	NULL
£	NULL
1	NULL
2	NULL
3	NULL
4	NULL
0	NULL
5	NULL
‘	NULL
-	NULL
80	NULL
-	NULL
49.5	NULL
c-Jun	NULL
--	NULL
32.5	NULL
6307	NULL
(	NULL
B	NULL
)	NULL
§	NULL
$	NULL
so	NULL
l	NULL
f	NULL
e	NULL
mo	NULL
&	NULL
0	NULL
3	NULL
P	NULL
eee	NULL
o	NULL
a	NULL
--	NULL
E	NULL
MW	NULL
(	NULL
kDa	NULL
)	NULL
jad	NULL
jued	NULL
Ao	NULL
a	NULL
é	NULL
5	NULL
&	NULL
£	NULL
1	NULL
2	NULL
3	NULL
``	NULL
s	NULL
,	NULL
-106	NULL
a	NULL
#	NULL
d	NULL
~	NULL
80	NULL
-	NULL
49,5	NULL
-	NULL
32.5	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
following	NULL
gel	NULL
retardation	NULL
.	NULL

Gel	NULL
retardation	NULL
assays	NULL
were	NULL
first	NULL
performed	NULL
with	NULL
Jurkat	NULL
T	NULL
cell	NULL
nuclear	NULL
extracts	NULL
(	NULL
following	NULL
activation	NULL
with	NULL
PHA	NULL
plus	NULL
PMA	NULL
)	NULL
and	NULL
either	NULL
the	NULL
-307	NULL
to	NULL
-288	NULL
AP-1	NULL
oligomer	NULL
or	NULL
the	NULL
-161	NULL
to	NULL
-142	NULL
NF-IL3A	NULL
oligomer	NULL
.	NULL

The	NULL
inducible	NULL
DNA-protein	NULL
band	NULL
derived	NULL
from	NULL
the	NULL
AP-1	NULL
oligomer	NULL
and	NULL
bands	NULL
NF-IL3A-1	NULL
and	NULL
NF-IL3A-2	NULL
derived	NULL
from	NULL
the	NULL
NF-IL3A	NULL
oligomer	NULL
were	NULL
excised	NULL
from	NULL
the	NULL
wet	NULL
gel	NULL
,	NULL
boiled	NULL
,	NULL
and	NULL
fractionated	NULL
in	NULL
SDS-polyacrylamide	NULL
gel	NULL
prior	NULL
to	NULL
membrane	NULL
transfer	NULL
.	NULL

Blots	NULL
were	NULL
probed	NULL
either	NULL
with	NULL
anti-c-Jun	NULL
(	NULL
A	NULL
)	NULL
or	NULL
anti-Oct-1	NULL
(	NULL
B	NULL
)	NULL
antibodies	NULL
.	NULL

A	NULL
,	NULL
lane	NULL
1	NULL
,	NULL
90	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
were	NULL
directly	NULL
loaded	NULL
onto	NULL
the	NULL
gel	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
gel	NULL
slice	NULL
containing	NULL
the	NULL
inducible	NULL
AP-1	NULL
complex	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
gel	NULL
slice	NULL
containing	NULL
the	NULL
NF-IL3A-2	NULL
complex	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
gel	NULL
slice	NULL
containing	NULL
free	NULL
NF-IL3A	NULL
probe	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
control	NULL
gel	NULL
slice	NULL
from	NULL
the	NULL
retardation	NULL
gel	NULL
containing	NULL
extract	NULL
alone	NULL
;	NULL
the	NULL
gel	NULL
slice	NULL
was	NULL
excised	NULL
from	NULL
a	NULL
position	NULL
immediately	NULL
adjacent	NULL
to	NULL
the	NULL
NF-IL3A-2	NULL
protein-DNA	NULL
complex	NULL
.	NULL

Molecular	NULL
mass	NULL
markers	NULL
are	NULL
indicated	NULL
in	NULL
kDa	NULL
.	NULL

B	NULL
,	NULL
lane	NULL
1	NULL
,	NULL
gel	NULL
slice	NULL
containing	NULL
the	NULL
NF-IL3A-1	NULL
complex	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
gel	NULL
slice	NULL
containing	NULL
the	NULL
free	NULL
NF-IL3A	NULL
probe	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
control	NULL
gel	NULL
slice	NULL
containing	NULL
extract	NULL
alone	NULL
and	NULL
excised	NULL
adjacent	NULL
to	NULL
the	NULL
NF-IL3A-1	NULL
complex	NULL
.	NULL

mary	NULL
T	NULL
cells	NULL
by	NULL
PMA	NULL
alone	NULL
at	NULL
concentrations	NULL
as	NULL
high	NULL
as	NULL
100	NULL
ng/ml	NULL
.	NULL

PMA	NULL
alone	NULL
is	NULL
capable	NULL
of	NULL
strongly	NULL
inducing	NULL
AP-1	NULL
binding	NULL
activity	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
lines	NULL
including	NULL
fibroblasts	NULL
and	NULL
Jurkat	NULL
cells	NULL
(	NULL
33	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
primary	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
have	NULL
recently	NULL
been	NULL
reported	NULL
to	NULL
minimally	NULL
augment	NULL
AP-1	NULL
binding	NULL
activity	NULL
whereas	NULL
PMA	NULL
in	NULL
combination	NULL
with	NULL
additional	NULL
stimulation	NULL
greatly	NULL
increased	NULL
AP-1	NULL
activity	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
PMA	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
induce	NULL
full	NULL
AP-1	NULL
binding	NULL
activity	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

Our	NULL
data	NULL
indicate	NULL
that	NULL
at	NULL
least	NULL
one	NULL
octamer	NULL
protein	NULL
(	NULL
most	NULL
likely	NULL
Oct-1	NULL
)	NULL
participates	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
IL3	NULL
by	NULL
binding	NULL
in	NULL
a	NULL
noninducible	NULL
manner	NULL
to	NULL
the	NULL
NF-IL3A	NULL
DNA	NULL
site	NULL
.	NULL

One	NULL
hypothesis	NULL
which	NULL
has	NULL
been	NULL
raised	NULL
to	NULL
explain	NULL
how	NULL
Oct-1	NULL
may	NULL
mediate	NULL
T	NULL
cell	NULL
gene	NULL
transcriptional	NULL
activation	NULL
despite	NULL
its	NULL
constitutive	NULL
expression	NULL
in	NULL
unstimulated	NULL
cells	NULL
postulates	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
separate	NULL
activator	NULL
which	NULL
,	NULL
following	NULL
cell	NULL
activation	NULL
,	NULL
interacts	NULL
with	NULL
Oct-1	NULL
to	NULL
induce	NULL
transcription	NULL
.	NULL

The	NULL
functional	NULL
activity	NULL
of	NULL
Oct-1	NULL
in	NULL
Jurkat	NULL
cells	NULL
requires	NULL
the	NULL
direct	NULL
interaction	NULL
of	NULL
Oct-1	NULL
with	NULL
a	NULL
mitogen-inducible	NULL
DNA	NULL
binding	NULL
``	NULL
Oct-1l-associated	NULL
protein	NULL
(	NULL
OAP40	NULL
)	NULL
``	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Oct-2	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
increase	NULL
the	NULL
functional	NULL
activity	NULL
of	NULL
Oct-1	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Our	NULL
studies	NULL
indicate	NULL
that	NULL
at	NULL
least	NULL
two	NULL
sets	NULL
of	NULL
transcriptional	NULL
regulators	NULL
interact	NULL
with	NULL
the	NULL
NF-IL3A	NULL
sequence	NULL
of	NULL
the	NULL
IL3	NULL
promoter	NULL
:	NULL
inducible	NULL
AP-1	NULL
binding	NULL
elements	NULL
and	NULL
constitutively	NULL
expressed	NULL
octamer	NULL
proteins	NULL
,	NULL
most	NULL
likely	NULL
Oct-1	NULL
.	NULL

We	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
direct	NULL
interaction	NULL
between	NULL
AP-1-	NULL
and	NULL
octamer-binding	NULL
proteins	NULL
by	NULL
mobility	NULL
shift	NULL
and	NULL
antibody	NULL
supershift	NULL
assays	NULL
,	NULL
even	NULL
though	NULL
UV	NULL
cross-linking	NULL
with	NULL
the	NULL
NF-IL3A	NULL
oligomer	NULL
demonstrated	NULL
two	NULL
different	NULL
proteins	NULL
migrating	NULL
in	NULL
SDS-polyacrylamide	NULL
gel	NULL
with	NULL
molecular	NULL
weights	NULL
consistent	NULL
with	NULL
c-Jun	NULL
and	NULL
Oct-1	NULL
.	NULL

The	NULL
possible	NULL
interaction	NULL
of	NULL
octamer	NULL
proteins	NULL
either	NULL
with	NULL
AP-1-binding	NULL
proteins	NULL
or	NULL
with	NULL
as	NULL
yet	NULL
unidentified	NULL
co-activators	NULL
to	NULL
induce	NULL
IL3	NULL
transcription	NULL
in	NULL
vivo	NULL
remains	NULL
speculative	NULL
but	NULL
is	NULL
suggested	NULL
by	NULL
the	NULL
multiple	NULL
protein-DNA	NULL
adducts	NULL
noted	NULL
with	NULL
the	NULL
NF-IL3A	NULL
oligomer	NULL
after	NULL
UV	NULL
cross-linking	NULL
.	NULL

Small	NULL
amounts	NULL
of	NULL
CAT	NULL
activity	NULL
were	NULL
observed	NULL
in	NULL
uninduced	NULL
constructs	NULL
from	NULL
-107	NULL
to	NULL
-356	NULL
whereas	NULL
the	NULL
-59	NULL
construct	NULL
consistently	NULL
produced	NULL
no	NULL
activity	NULL
in	NULL
either	NULL
prestimulated	NULL
cells	NULL
or	NULL
following	NULL
activation	NULL
with	NULL
CD2	NULL
or	NULL
PHA	NULL
plus	NULL
PMA	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
our	NULL
prestimulation	NULL
protocol	NULL
may	NULL
have	NULL
in	NULL
part	NULL
been	NULL
responsible	NULL
for	NULL
this	NULL
``	NULL
basal	NULL
``	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
several	NULL
pieces	NULL
of	NULL
evidence	NULL
are	NULL
against	NULL
this	NULL
possibility	NULL
.	NULL

First	NULL
,	NULL
no	NULL
IL3	NULL
message	NULL
was	NULL
detected	NULL
in	NULL
either	NULL
resting	NULL
or	NULL
prestimulated	NULL
T	NULL
cells	NULL
even	NULL
after	NULL
exposure	NULL
of	NULL
the	NULL
autoradiograms	NULL
for	NULL
as	NULL
long	NULL
as	NULL
one	NULL
week	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
constitutively	NULL
expressed	NULL
NF-IL3A-1	NULL
band	NULL
was	NULL
identical	NULL
in	NULL
both	NULL
resting	NULL
T	NULL
cells	NULL
and	NULL
in	NULL
prestimulated	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Third	NULL
,	NULL
mobility	NULL
shift	NULL
analysis	NULL
with	NULL
the	NULL
-307	NULL
to	NULL
-288	NULL
oligomer	NULL
(	NULL
containing	NULL
the	NULL
consensus	NULL
AP-1	NULL
site	NULL
)	NULL
demonstrated	NULL
the	NULL
same	NULL
6308	NULL
level	NULL
of	NULL
AP-1	NULL
binding	NULL
activity	NULL
in	NULL
both	NULL
resting	NULL
T	NULL
cells	NULL
and	NULL
in	NULL
prestimulated	NULL
T	NULL
cells	NULL
.	NULL

Fourth	NULL
,	NULL
two	NULL
specific	NULL
constitutive	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
detected	NULL
following	NULL
incubation	NULL
of	NULL
the	NULL
-98	NULL
to	NULL
-59	NULL
oligomer	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
resting	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
two	NULL
complexes	NULL
of	NULL
comparable	NULL
intensity	NULL
were	NULL
also	NULL
observed	NULL
following	NULL
incubation	NULL
with	NULL
extracts	NULL
from	NULL
prestimulated	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
low	NULL
level	NULL
of	NULL
activity	NULL
observed	NULL
in	NULL
our	NULL
uninduced	NULL
constructs	NULL
may	NULL
reflect	NULL
a	NULL
basal	NULL
level	NULL
of	NULL
IL3	NULL
transcription	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
as	NULL
well	NULL
as	NULL
others	NULL
have	NULL
demonstrated	NULL
constitutive	NULL
transcription	NULL
of	NULL
the	NULL
IL3	NULL
gene	NULL
by	NULL
nuclear	NULL
run-on	NULL
analysis	NULL
in	NULL
both	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
and	NULL
primary	NULL
T	NULL
cells	NULL
in	NULL
conjunction	NULL
with	NULL
very	NULL
unstable	NULL
IL3	NULL
mRNA	NULL
(	NULL
15	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
AU-rich	NULL
sequences	NULL
in	NULL
the	NULL
-untranslated	NULL
region	NULL
of	NULL
our	NULL
transfection	NULL
constructs	NULL
may	NULL
have	NULL
also	NULL
resulted	NULL
in	NULL
relatively	NULL
stable	NULL
CAT	NULL
messages	NULL
.	NULL

The	NULL
sequence	NULL
between	NULL
-107	NULL
and	NULL
-59	NULL
of	NULL
the	NULL
IL8	NULL
promoter	NULL
contains	NULL
a	NULL
consensus	NULL
binding	NULL
site	NULL
at	NULL
-74	NULL
to	NULL
-65	NULL
(	NULL
TCCCCCC	NULL
G	NULL
CC	NULL
)	NULL
for	NULL
the	NULL
transcription	NULL
factor	NULL
AP-2	NULL
(	NULL
43	NULL
)	NULL
,	NULL
and	NULL
one	NULL
consensus	NULL
binding	NULL
site	NULL
at	NULL
-70	NULL
to	NULL
-65	NULL
(	NULL
CCCGCC	NULL
)	NULL
for	NULL
the	NULL
transcription	NULL
factor	NULL
Sp1	NULL
(	NULL
44	NULL
)	NULL
.	NULL

The	NULL
possible	NULL
role	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
in	NULL
regulation	NULL
of	NULL
IL3	NULL
gene	NULL
expression	NULL
in	NULL
either	NULL
the	NULL
resting	NULL
state	NULL
or	NULL
following	NULL
cell	NULL
activation	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

Two	NULL
differences	NULL
were	NULL
observed	NULL
in	NULL
analysis	NULL
of	NULL
IL3	NULL
transcription	NULL
when	NULL
primary	NULL
T	NULL
cells	NULL
were	NULL
used	NULL
in	NULL
place	NULL
of	NULL
leukemic	NULL
cell	NULL
lines	NULL
.	NULL

Construct	NULL
-59	NULL
produced	NULL
no	NULL
CAT	NULL
activity	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
whereas	NULL
it	NULL
was	NULL
capable	NULL
of	NULL
driving	NULL
a	NULL
low	NULL
level	NULL
of	NULL
constitutive	NULL
IL3	NULL
promoter	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Control	NULL
experiments	NULL
with	NULL
B-galactosidase	NULL
plasmid	NULL
DNA	NULL
indicated	NULL
that	NULL
this	NULL
difference	NULL
could	NULL
not	NULL
be	NULL
ascribed	NULL
to	NULL
poorer	NULL
transfection	NULL
efficiency	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
second	NULL
difference	NULL
concerns	NULL
analysis	NULL
of	NULL
possible	NULL
negative	NULL
regulatory	NULL
elements	NULL
in	NULL
the	NULL
IL3	NULL
promoter	NULL
.	NULL

A	NULL
prominent	NULL
negative	NULL
regulatory	NULL
sequence	NULL
in	NULL
the	NULL
IL3	NULL
promoter	NULL
termed	NULL
NIP	NULL
(	NULL
between	NULL
-271	NULL
and	NULL
-250	NULL
)	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
MLA-144	NULL
cells	NULL
,	NULL
a	NULL
gibbon	NULL
T	NULL
cell	NULL
line	NULL
infected	NULL
with	NULL
the	NULL
gibbon	NULL
leukemia	NULL
virus	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
our	NULL
transfection	NULL
assays	NULL
performed	NULL
with	NULL
primary	NULL
T	NULL
cells	NULL
,	NULL
deletion	NULL
of	NULL
this	NULL
negative	NULL
element	NULL
had	NULL
only	NULL
a	NULL
relatively	NULL
modest	NULL
effect	NULL
on	NULL
reporter	NULL
gene	NULL
activity	NULL
(	NULL
comparing	NULL
constructs	NULL
-272	NULL
and	NULL
-161	NULL
)	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
strong	NULL
inhibitory	NULL
effect	NULL
observed	NULL
in	NULL
MLA-144	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Mobility	NULL
shift	NULL
assays	NULL
using	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
NIP	NULL
sequence	NULL
(	NULL
-271	NULL
to	NULL
-250	NULL
)	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
specific	NULL
retarded	NULL
band	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
or	NULL
PHA	NULL
plus	NULL
PMA-stimulated	NULL
primary	NULL
T	NULL
cells	NULL
or	NULL
Jurkat	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
UV	NULL
cross-linking	NULL
studies	NULL
with	NULL
this	NULL
oligomer	NULL
did	NULL
not	NULL
show	NULL
any	NULL
DNA-protein	NULL
adduct	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
NIP	NULL
activity	NULL
may	NULL
be	NULL
relatively	NULL
restricted	NULL
to	NULL
MLA-144	NULL
cells	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Dr.	NULL
Ellis	NULL
Reinherz	NULL
for	NULL
kindly	NULL
providing	NULL
anti-T11	NULL
;	NULL
and	NULL
anti-T11	NULL
;	NULL
hybridoma	NULL
clones	NULL
,	NULL
Dr.	NULL
Robert	NULL
Tjian	NULL
for	NULL
providing	NULL
antiserum	NULL
specific	NULL
to	NULL
human	NULL
c-Jun	NULL
,	NULL
and	NULL
Dr.	NULL
Inder	NULL
Verma	NULL
for	NULL
providing	NULL
M-2	NULL
antibody	NULL
directed	NULL
against	NULL
c-Fos	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Dr.	NULL
Winship	NULL
Herr	NULL
and	NULL
Dr.	NULL
Tom	NULL
Kristie	NULL
for	NULL
providing	NULL
antisera	NULL
against	NULL
Oct-1-	NULL
and	NULL
Oct-2-binding	NULL
proteins	NULL
and	NULL
acknowledge	NULL
Diana	NULL
Thompson	NULL
and	NULL
Margaret	NULL
Shatsky	NULL
for	NULL
expert	NULL
technical	NULL
assistance	NULL
.	NULL

bo	NULL
i	NULL
©	NULL
p	NULL
-g	NULL
goo	NULL
11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43.	NULL
.	NULL

Kadonaga	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Camer	NULL
,	NULL
K.	NULL
R.	NULL
,	NULL
Maslarz	NULL
,	NULL
F.	NULL
R.	NULL
,	NULL
and	NULL
lean	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
.	NULL

Mustelin	NULL
,	NULL
T.	NULL
,	NULL
Coggeshall	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Isakov	NULL
,	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
IL3	NULL
REFERENCES	NULL
.	NULL

Clark	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
and	NULL
Kamen	NULL
,	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Science	NULL
236	NULL
,	NULL
1229-1237	NULL
.	NULL

Arai	NULL
,	NULL
K.	NULL
,	NULL
Lee	NULL
,	NULL
F.	NULL
,	NULL
Miyajima	NULL
,	NULL
A.	NULL
,	NULL
Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Arai	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Yokota	NULL
,	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

59	NULL
,	NULL
783-836	NULL
.	NULL

Otsuka	NULL
,	NULL
T.	NULL
,	NULL
Miyajima	NULL
,	NULL
A.	NULL
,	NULL
Brown	NULL
,	NULL
N.	NULL
,	NULL
Otsu	NULL
,	NULL
K.	NULL
,	NULL
Abrama	NULL
,	NULL
J.	NULL
,	NULL
Saeland	NULL
,	NULL
S.	NULL
,	NULL
Caux	NULL
,	NULL
C.	NULL
,	NULL
De	NULL
Waal	NULL
Malefijt	NULL
,	NULL
R.	NULL
,	NULL
De	NULL
Vries	NULL
,	NULL
J.	NULL
,	NULL
Meyerson	NULL
,	NULL
P.	NULL
,	NULL
Yokota	NULL
,	NULL
K.	NULL
,	NULL
Gemmel	NULL
,	NULL
L.	NULL
,	NULL
Rennick	NULL
,	NULL
D.	NULL
,	NULL
Lee	NULL
,	NULL
F.	NULL
,	NULL
Arai	NULL
,	NULL
K.-L.	NULL
,	NULL
and	NULL
Yokota	NULL
,	NULL
T.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
2288-2295	NULL
.	NULL

Niemeyer	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Sieff	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Mathey-Prevot	NULL
,	NULL
B.	NULL
,	NULL
Wimperis	NULL
,	NULL
J	NULL
.	NULL

Z.	NULL
,	NULL
Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Clark	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
and	NULL
Nathan	NULL
D.	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
Blood	NULL
73	NULL
,	NULL
945-951	NULL
.	NULL

Weiss	NULL
,	NULL
A	NULL
Imboden	NULL
J	NULL
Hardy	NULL
,	NULL
K.	NULL
,	NULL
Manger	NULL
,	NULL
B.	NULL
,	NULL
Terhorst	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Stobo	NULL
,	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

4	NULL
,	NULL
'593-619	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
355-361	NULL
.	NULL

Samelson	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Patel	NULL
,	NULL
M	NULL
D.	NULL
,	NULL
Weissman	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Harford	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Klausner	NULL
,	NULL
R.	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
1083-1090	NULL
.	NULL

Klausner	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
O'Shea	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Luong	NULL
,	NULL
H.	NULL
,	NULL
Ross	NULL
,	NULL
P.	NULL
,	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Samelson	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Brol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
12654-12659	NULL
.	NULL

June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Fletcher	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Schieven	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Siegel	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Phillips	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
and	NULL
Samelson	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
7722-7726	NULL
N.	NULL
,	NULL
and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
247	NULL
,	NULL
1584-1587	NULL
Geppert	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
Davis	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
Gur	NULL
,	NULL
H.	NULL
,	NULL
Wacholtz	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
and	NULL
Lipsky	NULL
,	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

117	NULL
,	NULL
5-66	NULL
Guba	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Stella	NULL
,	NULL
G.	NULL
,	NULL
Turka	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
and	NULL
Emerson	NULL
,	NULL
S.	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

84	NULL
,	NULL
1701-1706	NULL
Mathey-Prevot	NULL
,	NULL
B.	NULL
,	NULL
Andrews	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Murphy	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
Kreissman	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
and	NULL
Nathan	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
5046-5050	NULL
Shoemaker	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Hromas	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Kaushansky	NULL
,	NULL
K.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
9650-9654	NULL
Ryan	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Milton	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Lopez	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
Bardy	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Vadas	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Shannon	NULL
,	NULL
M.	NULL
F.	NULL
(	NULL
1991	NULL
)	NULL
Blood	NULL
77	NULL
,	NULL
1195-1202	NULL
Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Nolan	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
2734-2739	NULL
Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
Nolan	NULL
,	NULL
P.	NULL
,	NULL
Inaba	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Steinman	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1869-1872	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Higgins	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1617-1620	NULL
Gillis	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Watson	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

152	NULL
,	NULL
1709-1719	NULL
Thevenin	NULL
,	NULL
C.	NULL
,	NULL
Kim	NULL
,	NULL
S.-J	NULL
.	NULL

,	NULL
and	NULL
Kehrl	NULL
,	NULL
J.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
9363-	NULL
66	NULL
93	NULL
Zehnder	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Hirai	NULL
,	NULL
K.	NULL
,	NULL
Shatsky	NULL
,	NULL
M.	NULL
,	NULL
McGregor	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Levitt	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
and	NULL
Leung	NULL
,	NULL
L.	NULL
L.	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
J	NULL
Biol	NULL
,	NULL
Chem	NULL
267	NULL
,	NULL
5243-5249	NULL
Shaw	NULL
,	NULL
J.-P.	NULL
,	NULL
Utz	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Toole	NULL
J.	NULL
J.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
'	NULL
a	NULL
.	NULL

R.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
202—205	NULL
Cann	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Koyanagi	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Chen	NULL
,	NULL
I.	NULL
S.	NULL
Y	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Oncogene	NULL
8	NULL
,	NULL
123-128	NULL
MacGregor	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Mogg	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Burke	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
and	NULL
Caskey	NULL
,	NULL
C.	NULL
T.	NULL
(	NULL
1987	NULL
)	NULL
Somatic	NULL
Cell	NULL
Mol	NULL
.	NULL

Genet	NULL
.	NULL

18	NULL
,	NULL
253-265	NULL
Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
,	NULL
2nd	NULL
Ed	NULL
.	NULL

,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
Dignam	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Lebovxtz	NULL
,	NULL
R	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475—	NULL
89	NULL
Wu	NULL
,	NULL
F.	NULL
K	NULL
Garcm	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Harrich	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Gaynor	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
2117	NULL
Mohtor	NULL
,	NULL
J	NULL
A	NULL
Walker	NULL
,	NULL
W	NULL
H.	NULL
,	NULL
Doerre	NULL
,	NULL
S.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
10028-	NULL
10032	NULL
Meuer	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Hussey	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Fabbi	NULL
,	NULL
M.	NULL
,	NULL
Fox	NULL
,	NULL
D	NULL
Acuto	NULL
,	NULL
O.	NULL
,	NULL
Fitzgerald	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Hodgdon	NULL
,	NULL
J	NULL
C.	NULL
,	NULL
Protentm	NULL
J.	NULL
P	NULL
Schlossman	NULL
S.	NULL
F	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1984	NULL
)	NULL
Cell	NULL
86	NULL
,	NULL
897-906	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
van	NULL
Beveren	NULL
,	NULL
C.	NULL
,	NULL
Ling	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

5	NULL
,	NULL
167-172	NULL
Sturm	NULL
,	NULL
R	NULL
A.	NULL
,	NULL
Das	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Herr	NULL
,	NULL
W.	NULL
(	NULL
1988	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

2	NULL
,	NULL
1582-1599	NULL
Knstle	NULL
,	NULL
T.	NULL
M	NULL
Lebothz	NULL
,	NULL
J	NULL
H.	NULL
,	NULL
and	NULL
Sharp	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
EMBOJ	NULL
8	NULL
,	NULL
4229-4238	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Rahmsdorf	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Jonat	NULL
,	NULL
C	NULL
Herrlich	NULL
,	NULL
P	NULL
and	NULL
Karm	NULL
,	NULL
M	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
1729-739	NULL
Mxtchell	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
’	NULL
I	NULL
‘	NULL
]	NULL
1an	NULL
,	NULL
R	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
245	NULL
,	NULL
371—378	NULL
Berry	NULL
,	NULL
N	NULL
Ase	NULL
K	NULL
Kikkawa	NULL
,	NULL
U.	NULL
,	NULL
Kishimoto	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Immune	NULL
!	NULL

143	NULL
1407—1413	NULL
Farrar	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
and	NULL
Ruscetti	NULL
,	NULL
F.	NULL
W.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

136	NULL
,	NULL
1266-1273	NULL
Hanecom	NULL
,	NULL
C.	NULL
,	NULL
Nel	NULL
,	NULL
A.	NULL
,	NULL
Gittinger	NULL
,	NULL
C.	NULL
,	NULL
Rheeder	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Landreth	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

262	NULL
449-456	NULL
Nel	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Hanecom	NULL
,	NULL
C.	NULL
,	NULL
Rheeder	NULL
,	NULL
A.	NULL
,	NULL
Williams	NULL
,	NULL
K.	NULL
,	NULL
Pollack	NULL
,	NULL
S.	NULL
,	NULL
Katz	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Landbeth	NULL
,	NULL
G.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
2683-2689	NULL
Sturgill	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
and	NULL
Wu	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Bwphys	NULL
Acta	NULL
1092	NULL
,	NULL
350-357	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Boyle	NULL
W.	NULL
,	NULL
Meek	NULL
,	NULL
J.	NULL
,	NULL
Smeal	NULL
T.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
'M	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cell	NULL
54	NULL
541-552	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
Edwards	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
254	NULL
558-562	NULL
Kamps	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Corcoran	NULL
,	NULL
L	NULL
Lebowitz	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
5464-5472	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chm	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
51	NULL
,	NULL
251-260	NULL
51	NULL
,	NULL
1079-1090	NULL

